
## June 22-23, 2022

Welcome to Day 2 We will begin shortly...

# NIH Cloud Platform Interoperability Spring 2022 Virtual Workshop



## Today's Agenda

#### Day 2: Thursday, June 23, 2022

11:00 AM - 11:05 AM - Welcome and start of Day 2 Stephen Mosher (Johns Hopkins University)

#### **Interoperability Driven Science**

Cloud platform interoperability enables scientific discovery. Here we will learn of the latest advances in NCPI demonstration projects and related cloud platforms.

11:05 AM - 11:20 AM - The ELIXIR Cloud for European Life Sciences Jonathan Tedds (ELIXIR)
11:20 AM - 11:35 AM - Sex chromosome complement aware alignments Melissa Wilson (ASU)
11:35 AM - 11:50 AM - Genome-wide Sequencing Analysis to Identify the Genes Responsible for Enchondromatoses and Related Malignant Tumors. Nara Sobreira (JHU)
11:50 AM - 1:05 PM - Working Group Updates
15 min - Community/Governance WG

Bob Grossman (University of Chicago) Stanley Ahalt (University of North Carolina at Chapel Hill) 15 min - Systems Interoperation WG Jack DiGiovanna (SevenBridges) 15 min - FHIR WG Robert Carroll (Vanderbilt University Medical Center) 15 min - NCPI Outreach WG Stephen Mosher (Johns Hopkins University) 15 min - Search WG Dave Rogers (Clever Canary) Kathy Reinold (Broad Institute)

1:05 PM - 1:35 PM - Break

#### **Technical Aspects of Interoperability**

Technologies that enable interoperability are important to develop with stakeholders involved to promote the usability of the technical standards and products. In this session, we will hear about technologies enabling interoperability and their successful implementations in research.

1:35 PM - 1:50 PM - The Texas Advanced Computing Center (TACC) as an Interoperable Cloud Resource for Biomedical Research Dan Stanzione (TACC)
1:50 PM - 2:05 PM - FHIR for Genomics: The Path Forward Mullai Murugan (Baylor College of Medicine)
2:05 PM - 2:20 PM - Supporting Genomic Data Sharing through the Global Alliance for Genomics and Health Heidi Rehm (Broad Institute)
2:20 PM - 2:35 PM - Interoperability Opportunities & Challenges with the Cloud and STRIDES Nick Weber (NIH STRIDES)

#### 2:35 PM - 3:10 PM - Concurrent Breakouts

Topic 1: Bringing researchers to cloud computing Topic 2: Reproducibility and Interoperability of batch and ad hoc analyses Topic 3: What technologies and data types are missing across platforms? Topic 4: Diversifying genomic data science Topic 5: Flagship use cases for interoperability

#### Day 2 Breakout Moderators

Topic 1: Bringing researchers to cloud computing	Tiffany Miller
Topic 2: Reproducibility and Interoperability of batch and ad hoc analyses	Jack DiGiovanna
Topic 3: What technologies and data types are missing across platforms?	Ken Wiley
Topic 4: Diversifying genomic data science	Asiyah Lin
Topic 5: Flagship use cases for interoperability	Michael Schatz

3:10 PM - 3:50 PM - Report Back

5 minutes for report prep; 5 minute report per group; 10 minutes open discussion

3:50 PM - 4:00 PM – Summary, Future Directions, & Meeting close Michael Schatz (Johns Hopkins University)

# Interoperability Driven Science



11:05 AM - 11:50 AM EDT

# The ELIXIR Cloud for European Life Sciences



Jonathan Tedds (ELIXIR)

## The ELIXIR Cloud for European Life Sciences NCPI Meeting, 23 June 2022



Jonathan Tedds (Compute, Tools Platform & EOSC Coordinator)

www.elixir-europe.org


#### A sustainable infrastructure for biological data





#### **ELIXIR Observers**






#### ELIXIR Services for all domains of life sciences

The ELIXIR Nodes collectively run hundreds of bioinformatics services, where:

- <u>5 Platforms</u> coordinate services across all scientific domains and all the Nodes
- <u>13 Communities</u> work in a particular domain and give feedback on platform services
- <u>12 Focus groups</u> bring together people with an interest in a particular topic
- <u>EU projects</u> & <u>internal projects</u> drive development of services and knowledge exchange

The vast majority of **ELIXIR services** are available free of charge and accessible globally by anyone interested






More: <u>elixir-europe.org/how-we-work</u>

#### Accessing ELIXIR Cloud and beyond: Life Science Login

- Common AAI for 13 European life
   science research infrastructures
- ELIXIR a major contributor
- Uses common internet standards
- Successful ELIXIR AAI migration to LS Login for users, April 2022
  - Services to follow
- Sustainable post-project service model
  - Community driven




## Services & Solutions

<b>- Galaxy</b> PROJECT	WorkflowHub	ELIXIR::GA4GH Cloud
Web-based platform for reproducible computational analysis	Registry for describing, sharing and publishing scientific computational workflows	Federated, interoperable network of workflow engines and compute nodes based on GA4GH standards
ELIXIR Community	EOSC-Life resource	GA4GH Driver Project
APIs & (third-party) GUIs	API & GUI	APIs & third-party GUIs



## How we work





## Relevant GA4GH APIs



#### Passport

Grant access to data & compute



#### **TRS: Tool Registry Service API**

Access workflows and container images



#### **DRS: Data Repository Service API**

Access to data sets




#### **WES: Workflow Execution Service API**

Interpret workflows & schedule task execution



#### TES: Task Execution Service API


Execute tasks



## Moonshot demonstrator (8th GA4GH Plenary)



Goal: Showcase reproducibility of GA4GH Cloud implementations



#### ELIXIR Cloud resources for COVID-19 response

#### Find computing resources to help you analyse datasets

ELIXIR runs computing services that can be accessed by research projects. Many additional computing resources have been made available to support COVID-19 research projects and a number offer access to Docker Orchestrators, including Mesos and OpenStack access, Kubernetes/OKD and potentially GPUs where needed. For assistance please contact jonathan.tedds@elixir-europe.org, ELIXIR's Compute Platform Coordinator. Examples of compute resources include:

- de.NBI cloud (ELIXIR Germany) provides priority access for projects relating to COVID-19.
- CSC (ELIXIR Finland) has prioritised access to its cloud services for COVID-19 research.
- e-INFRA CZ (ELIXIR Czech Republic) offers relaxed access conditions to supercomputer resources, storage services and distributed compute resources.
- EMBL-EBI is contributing EMBASSY Cloud resources as detailed on the European Open Science Cloud, EOSC Marketplace.
- A specific Galaxy COVID-19 instance for genomic analysis is available through Laniakea, ELIXIR Italy's ondemand platform.
- The European Galaxy server is an open, web-based platform for data intensive research and provides access to compute and storage resources. There are more than 2,500 different scientific tools, specific COVID-19 training materials, and workflows to guide users through COVID-19 data analysis.
- SIB (ELIXIR Switzerland) is providing a ready-to-use slurm workload manager with a scientific software stack via the ExPASy SIB Portal.
- IFB (ELIXIR France) is providing a federated set of high performance compute and cloud resources including
  national and regional servers.



#### Implementation Example



#### de.NBI – Deutsches Netzwerk für Bioinformatik Infrastruktur

TRAINING

#### de.NBI consortium

- 42 project partners
- 32 institutions
- 8 service centers
- designated national German node in ELIXIR

#### de.NBI mission

 Provision of comprehensive first-class bioinformatics services to users in basic and applied life sciences research

GERMANY

applacet to a

Bundesministerium für Bildung

und Forschung

- Bioinformatics training in Germany and Europe through a wide range of workshops and courses
- Cooperation of the German
   bioinformatics community with INTERNATIONAL
   cooperation
   international bioinformatics network
   structures







#### de.NBI Cloud Federation




- fully academic cloud federation
- Established 2016
- provides **storage and computing resources** for the life sciences community
- free of charge for academic use
- federation is maintained by the six German cloud centers located in Bielefeld, Heidelberg, Berlin, Freiburg, Giessen and Tübingen
- de.NBI Cloud offers a solution to enable integrative analyses, the efficient use of data in research, and computational capacities for bioinformatics training.

https://cloud.denbi.de




## de.NBI Cloud Infrastructure

#### Largest scientific cloud in Germany and one of the leading European academic clouds in life sciences





## **Project Numbers**




de.NBI Cloud Projects

Q1 2021: 323 OpenStack projects, 137 SimpleVM projects



- Full OpenStack Environment per Project For fully customizable provisioning and
- deployment of VMs and Services / Clusters
- Custom project-type based on OpenStack
- For simple deployment of VMs and Services / Clusters and integration of e.g. Bioconda



#### de.NBI Cloud ELIXIR AAI Users



## **Global Alliance for Genomics & Health**




#### GA4GH WES implementation

https://gitlab.com/one-touch-pipeline/weskit

#### Features

- WES for Snakemake and Nextflow
- Developed for high data throughput usage at Charité Universitätsmedizin Berlin and DKFZ
- HPC and Cloud deployment supported



## ELIXIR Cloud: Gap analysis



- Interoperable cost transfer / payment system
  - Okay for commercial clouds, but how about academia?
  - Science credits, credit cards, crypto? Not easy...
- Access control
  - Concrete vision of access control via Passport only shaping up now planning for European Genomic Data Infrastructure project 2022+
  - But only for data so far, can ELIXIR spearhead compute access?
- Sensitive data
  - How to secure data beyond access control
  - Crypt4GH, multi-party homomorphic encryption: how to integrate with Cloud APIs?
- > Technical implementation support
  - COVID-19 response illustrated the importance of skilled technical support

# Sex chromosome complement aware alignments



Melissa Wilson (ASU)

# Sex chromosome complement aware alignment **Brendan Pinto and Melissa Wilson**

## Many Thanks



#### **Brian O'Connor**

@boconnor

**Michael Schatz** 

@mike\_schatz

Samantha Zarate

@sz\_genomics

#### Who are we?




**Brendan Pinto** 

@drpintothe2nd




**Melissa Wilson** 

@sexchrlab




## Sex chromosomes share sequence similarity


- The X and Y chromosomes share sequence similarity due to shared evolutionary ancestry that affects alignments and quantification of NGS data
- PARs share 100% homology



## Human karyotype



## Human reference genome





Realign with appropriate sex chromosome masks

## **XX samples**: hard mask chrY

XY samples: hard mask PARs on chrY

## Workflow overview

Data: 15 female (XX) samples (GTEX)

- 1. Convert CRAM to BAM format (samtools)
- Strip reads from GRCh38 BAM files (samtools/bbmap)
   4.1. Trim reads + FastQC (Trim Galore!)
- 3. Re-map reads to CHM13v2.0 (bwa/samtools)
  - a. Karyotype aware (Y hard-masked)
  - b. Karyotype unaware (default)
- 4. Call haplotypes (GATK)
- 5. Call variants GenotypeVCFs (GATK)

## Called SNPs overview: "X vs. Autosome"

Total numbers of quality-filtered, biallelic SNPs called:

Chromosome	Unaware (GenBank*)	Aware (XYalign)	% change (A/U)
chr8	567,459	566,549	-0.17%
chrX	363,652	418,786	+15.2%

## Called SNPs overview: X chromosome breakdown

Total numbers of quality-filtered, biallelic SNPs called:


chrX Region	Unaware (GenBank*)	Aware (XYalign)	% change (A/U)
PAR (2.8 Mbp)	34	1,118	+3,188.2%
XTR (4.7 Mbp)	15,103	19,140	+26.7%
non-PAR (151 Mbp)	348,515	398,528	+14.4%

## Called SNPs overview: X chromosome breakdown

Total numbers of quality-filtered, biallelic SNPs called:

chrX (intragenic) regions	Unaware (GenBank*)	Aware (XYalign)	% change (A/U)
PAR (1.3 Mbp)	7	410	+5,757.1%
XTR (1.0 Mbp)	2,863	3,841	+34.2%
non-PAR (59.3 Mbp)	120,317	140,683	+16.9%

## ANAWZEALTHEGENOMESP



## Consistent issues

Most issues that we ran into can be binned into two categories:

- Unhelpful WOMtool validation errors (specifically when porting to Terra), e.g.
  - a. Error message: "ERROR: Unexpected symbol (line 6, col 5) when parsing 'setter'. Expected equal, got
     "String". String bam\_to\_reads\_mem\_size ^ \$setter = :equal \$e -> \$1"
  - b. Translation: "WDL missing a dedicated inputs section."
  - c. Why is this an issue? Unhelpful error messages inhibit forward progress.

#### Issues continued

#### 2. Data localization during analysis, e.g.

- a. Error message (GATK): "A USER ERROR has occurred: ... Cannot read non-existent file: <PATH-TO-VERY-EXISTENT-FILE.txt>"
- b. Translation: "GATK cannot stream data from your Google Bucket, try something else."
- c. Work-around: Copy all inputs into the working directory for each WDL task call input as a String instead of a File..



Hi Beri, there was no fix, only a hack - I wrote a WDL to copy the files to the workspace, then ran on those.

1) The error was:

A USER ERROR has occurred: Couldn't read file. Error was: drs:/dataguids.org/76cc4177-cf95-4

The issue is that the drs:// file paths are not being resolved to gs:// paths. My suspicion is that the WDL workflow defining the inputs barns as Array[String] rather than Array[File] may be causing the

#### file localization not working



(Many) fatal

new errors!

errors, but not

Philipp Hahnel 7 months ago- 18 comments

Follow

Hi, I've checked the other related articles on issues with file localization, and my problem doesn't seem to be amongst those. I've written a WDL to use samtools on a bam and a ref fasta.

1. Problem: The bai does not localize, all other files are localized:

2021/11/22 19:12:43 Starting container setup.

## In summary...

• We can do really incredible things with sex chromosome complement aware alignments to improve variant calling

• We can do this at scale on Terra

- It's going to take us a while longer to figure out how to do this at scale on Terra
  - Getting started on Terra adding odd Terra-specific quirks for beginners?

Genome-wide Sequencing Analysis to Identify the Genes Responsible for Enchondromatoses and Related Malignant Tumors



Nara Sobreira (Johns Hopkins University)

# Genome-wide Sequencing Analysis to Identify the Genes Responsible for Enchondromatoses and Related Malignant Tumors


Renan Martin

Nara Sobreira


Johns Hopkins University School of Medicine

# Scientific question

Are pathogenic variants in genes related to HIF-1 pathway mutated in patients with Ollier disease and Maffucci syndrome and in patients with isolated forms of gliomas and chondrosarcomas?




## 25% of the patients have variants in one of 7 genes related to the HIF-1 pathway



Regulation of HIF-1 $\alpha$  degradation at normoxia and hypoxia. \* Genes found mutated in patients with OD or MS.

Glioma and chondrosarcoma samples



## Interoperability plan

- Access germline WGS data from 61 probands (trios) with Ollier disease and Maffucci syndrome sequenced as part of the Gabriella Miller Kids First Pediatric Research Program and stored in CAVATICA
- Access germline WES data from 33 probands with Ollier disease and Maffucci syndrome sequenced as part of the BHCMG-CMG Program and stored in AnVIL
- Access tumor (and corresponding non-tumor tissue) WGS data from 816 patients from the Pediatric Brain Tumor Atlas (CBTN and PNOC)
  - ✔ Data will be accessed through the Kids First Program Data Resource Center and CAVATICA
- Access tumor WGS data from 878 patients with chondrosarcoma (PNOC)
  - Data will be accessed through the National Cancer Institute's Cancer Research Data Commons (NCI CRDC)

## Pediatric Brain Tumor Atlas Datasets

# CBTN

CRDC dataset (within CCDI)

- 998 probands
- 783 with VCF (harmonized pipeline)

# PNOC

Kids First Collaborator dataset

• 79 probands

• 33 with VCF (harmonized pipeline)

Status

• Already accessible through CAVATICA

it DRC Help Ce / 😻 Studies and Access				Q Search Duplicate ••••
Aligned Reads Individual gVCFs This dataset includes genomic data that are c	Aligned Reads Individual gVCFs	Aligned Reads Individual gVCFs Family-Base This dataset includes genomic data that are c		
This dataset includes genomic data that are c		This dataset includes genomic data that are c		
Kids First: Familial Leukemia	Kids First: Orofacial Cleft - African and	Kids First: Novel Cancer Susceptibility in	Kids First: Osteosarcoma	Kids First: Craniofacial Microsomia
NIH X01 Project Abstract - Charles Mullighan, PI	Asian Ancestry	Families (from BASIC3)	NIH X01 Project Abstract - Kenan Onel, Pl	NIH X01 Project Abstract - Daniela Luquetti, Pl
phs001738 dbGaP Study Page	NIH X01 Project Abstract - Azeez Butali and Te	NIH X01 Project Abstract - Sharon Plon, Pl	phs001714 dbGaP Study Page	phs002130 dbGaP Study Page
VCFs Aligned Reads Unaligned Reads	phs001997 dbGaP Study Page	phs001878 dbGaP Study Page	Aligned Reads	Aligned Reads Individual gVCFs Family-Bas
	Aligned Reads Individual gVCFs	Aligned Reads Individual gVCFs Family-Base		This dataset includes genomic data that are c
	This dataset includes genomic data that are c			
Kids First: Kidney and Urinary Tract	Kids First: Microtia - Hispanic	Kids First: Intersections of Cancer & SBD	Kids First: Esophageal Atresia and	Kid First: Hemangiomas (PHACE)
Defects	NIH X01 Project Abstract - Jonathan Seidman,	NIH X01 Project Abstract - Hakon Hakonarson,	Tracheoesophageal Fistulas	NIH X01 Project Abstract - Dawn Siegel, Pl
NIH X01 Project Abstract - Ali Gharavi, Pl	phs002172 dbGaP Study Page	phs001846 dbGaP Study Page	NIH X01 Project Abstract - Wendy Chung, Pl	phs001785 dbGaP Study Page
phs002162 dbGaP Study Page	Aligned Reads	Aligned Reads Individual gVCFs Family-Base	phs002161 dbGaP Study Page	Aligned Reads Individual gVCFs Family-Bas
Aligned Reads Individual gVCFs Family-Base			Aligned Reads	This dataset includes genomic data that are c
Kids First: Nonsyndromic	Kids First: Myeloid Malignancies	Kids First: Leukemia & Heart Defects in	Kids First: T-Cell ALL	
Craniosynostosis	NIH X01 Project Abstract - Soheil Meshinchi, Pl	Down Syndrome	NIH X01 Project Abstract - David Teachey, Pl	
NIH X01 Project Abstract - Simeon Boyd, Pl	phs002187 dbGaP Study Page	NIH X01 Project Abstract - Philip Lupo and Ste	phs002276 dbGaP Study Page	
phs001806 dbGaP Study Page	Aligned Reads Individual gVCFs Family-Base	phs002330 dbGaP Study Page	Aligned Reads VCFs	
Aligned Reads Individual gVCFs Family-Base		Aligned Reads Individual gVCFs Family-Base		

🗉 Gallery View 🗄 Table View



## **Pediatric Brain Tumor Atlas: CBTTC**

First Portal Releas... June 18, 2018
 Data Types Availa... Aligned Reads VCFs
 Sequencing Center Multiple
 About the Study CBTTC Website
 Applying for Acce... CBTTC Data Access Form
 Data Access Com... CBTTC Data Access Committee
 Known Data Issues CBTTC clinical event data is coll biospecimen, most often a tumo

ues CBTTC clinical event data is collected in a way that associates a diagnosis to a biospecimen, most often a tumor. A participant can have multiple tumors over time that have different diagnoses. Currently, this data in the Kids First Data Resource Portal is being presented as a diagnosis being attached to the participant and the association between tumor and diagnosis is not being displayed. This issue is being worked on. In the meantime, a list of diagnoses and directly associated clinical events is available by emailing support@kidsfirstdrc.org.



## Children's Brain Tumor Network Until every child is cured

Returning?
ΑΑΑ
÷ =

### **CBTN Request Form**

NOTE: Sample processing at the Operations Center and sample shipments may be delayed due to limited on-site personnel. Once you submitted your request and it is approved, we will provide the timeline by which we would deliver your specimens. We thank you for your patience and understanding during this time.

### Please complete the Specimen/Data Use Request Form below.

Please keep in mind the following timeline after the submission of your request. All time is in business days.

### **Specimen Requests:**

A primary reviewer reviews specimen requests within two weeks, and then the CBTN scientific committee has two weeks for any additional questions/comments.

Cell line requests will be reviewed within a week of submission by the Operations Center and Scientific co-Chair(s)

### Data Use Requests:

### CBTN Institutions: Raw Genomic Data, Clinical Data, Imaging

1. The request is reviewed for completeness by the CBTN Operations Center (1 day) 2. Access to the data is granted

### Non-CBTN Institutions: Clinical Data, Imaging

1. The request is reviewed for completeness by the CBTN Operations Center (1 day) 2. Access to the data is granted.

### Non-CBTN Institutions: Raw Genomic Data,

- 1. The request is reviewed for completeness by the CBTN Operations Center (1 day)
- 2. The request is submitted to the CBTN Data Use Committee for review. The committee has one week for review/questions/comments.
- 3. The investigator is responsible for providing executed DUA per NIH GDS requirements for the release of data.

If you have any questions or concerns regarding either process, please email <u>research@cbtn.org</u>. For additional information about CBTN, please visit <u>CBTN.org</u>.


### What are you requesting:

\* must provide value

SpecimensData

Kids First	☆ Dashboard	🖽 Studies	兇 Explore Data	🗄 Variant 🛛 File	Repository	오 Membe	ers						Reso	Ne urces		0	Nara	
E		St	udies															
Search Studies (i)																		
KF-DSD, Neuroblastom	1a		Program = Pedia	atric Brain Tumor Atlas 🗙											2	J	Ū	
∨ Domain																		-
Select All None			+ New query															
Cancer	2																	
✓ Program			Showing 2 studies															
				14. Herein			02000040				A	vailable	partici	pants	per Da	ata Cat	tegory	
Select All None			Code	Name	Progr	ram	Domain	dbGap	Participants	Families	Seq	Snv	Cnv	Exp	Sv P	Pat	Rad	С
Pediatric Brain Tun				Dediatria Drain Turran A	tion: Do-li-	trie Drein	Concer		70	0	66	50		20				
Kids First	24		PBTA-PNOC	Pediatric Brain Tumor A PNOC		atric Brain or Atlas	Cancer		79	0	66	59		30				
TARGET	2						Contest		5044	4510	002	744		1	~	001	040	
CARING	1		PBTA-CBTN	Pediatric Brain Tumor A CBTTC		atric Brain or Atlas	Cancer		5944	4512	992	744		1	5	901	248	8
ICR	1								6023	4512	1058	803	0	31	0 9	901	248	8
												500	-				- 10	
✓ Family Data																		
False	1																	

Kids First Charles Control Con	rd 🗉 Studies	ର୍ନ୍ଧ Explore Data	🗄 Variant 🛛 🗅 File Repos	sitory 🏾 🛛 Membe	ers					New Resources V	🕑 Nara 🗸
⊡ Security Objectives ⊙		KF-ED	Kids First: Enchondromatoses	Kids First	Cancer	<u>phs001987</u>	82	28	82	82	
Search Studies ① KF-DSD, Neuroblastoma		KF-OCEA	Kids First: Orofacial Cleft - European Ancestry	Kids First	Birth Defect	phs001168	1414	474	1295	1295	
∨ Domain		KF-TALL	Kids First: T Cell ALL	Kids First	Cancer	phs002276	1133	0	1133	1133	
Select All None	16	<u>KF-GMHP</u>	Kids First: Microtia - Hispanic	Kids First	Birth Defect	<u>phs002172</u>	334	182	334	334	
Cancer	10	<u>KF-GNINT</u>	Kids First: Intersections of Cancer & SBD	Kids First	Cancer, Birth Defect	<u>phs001846</u>	1777	1467	1776	1776	
∨ Program		KF-OFCLA	Kids First: Orofacial Cleft - Latin American	Kids First	Birth Defect	<u>phs001420</u>	804	271	804	804	
Select All   None		KF-FALL	Kids First: Familial Leukemia	Kids First	Cancer	<u>phs001738</u>	365	56	365	365	
<ul> <li>Kids First</li> <li>Pediatric Brain Tumor Atlas</li> </ul>	24	KF-CM	Kids First: Craniofacial Microsomia	Kids First	Birth Defect	<u>phs002130</u>	245	81	222	222	
CARING	2	KF-SCD	Kids First: Syndromic Cranial Dysinnervation	Kids First	Birth Defect	<u>phs001247</u>	801	248	801	801	
ICR	1	<u>KF-KUT</u>	Kids First: Kidney and Urinary Tract Defects	Kids First	Birth Defect	<u>phs002162</u>	132	44	132	132	



	nboard 🖽	Studies	冬 Explore	Data 🗏 Vari	iant 🗅 File Re	epository R	Members	Resources 🗸	Q
Filter Browse All	*		CLEAR STUDY	Y PROGRAM is	Vediatric Brain Tumor	Atlas ×	~ 5	hare 💿 Sa	ve
Clinical Filters File File File File File File File File	lters Q		48,358 File	es 🏌 1,0	78 Participants	<b>998</b> F	amilies	404.74 TB s	Size
	# FILES	c	howing to Ap						*
Pediatric Brain Tumor Atlas: CBTTC	44,176		- 20	alyze in Cavatica	a Download	I ∨ ≟ Fil	e Manifest	Columns V	Ľ
Pediatric Brain Tumor Atlas: PNOC	4,182	4	1 8,358 les						
Study Domain	Q		File ID	Participant	dbGap	Study Code	Proband	Family Id	Data
	# FILES		GF_CESZR6	PT_WGVEF9		PBTA-PNOC			Not I
Cancer	48,358		<u>GF_WAZQEY</u>	PT_C5FKRB1P		PBTA-PNOC			Aligr
Study Program	۹		<u>GF_3W8B37</u>	PT_1AAYYG		PBTA-PNOC			Aligr
	# FILES		<u>GF_5426M4</u>	<u>PT_1YQH5N</u>		PBTA-PNOC			Unal
Kids First									Reac
	48,358			PI M9XXIA		PBTA-PNOC			Not I
Pediatric Brain Tumor Atlas	48,358 3,490								
Kids First Pediatric Brain Tumor Atlas TARGET ICR			<u>GF_MGV9H</u>	PT_CSKHQB		PBTA-PNOC			Not I

Data Category         C           FILES         GF_ITSDPXSZ         PT_CSRHOB         PBTA-PNOC         Va           Simple Nucleotide Variation         6313         GF_IDDRXIL         PT_RE6AXQ         PBTA-PNOC         Va           No Data         6313         GF_IDDRXIL         PT_RE6AXQ         PBTA-PNOC         Va           Variant Calls         5948         GF_IDDRXIL         PT_RE6AXQ         PBTA-PNOC         Va           Nasked Somatic Mutation         1.865         GF_EDDRXIL         PT_RE6AXQ         PBTA-PNOC         Va           Masked Somatic Mutation         1.865         GF_EDDRXIL         PT_NESTZZES         PBTA-PNOC         Va           Somatic Structure Variant Calls         05.84W2         PT_V1HMAC         PBTA-PNOC         Va           Somatic Structure Varianton         1.895         GF_EDDRXIL         PT_RE5TZZES         PBTA-PNOC         Va           O 3 More         GF_A1BYVQ         PT_A05JR0ES         PBTA-PNOC         Va           Variant Call         702         GF_A1BYVQ         PT_A05JR0ES         PBTA-PNOC         Va           Variant Call         782         GF_A1BYVQ         PT_A05JR0ES         PBTA-PNOC         Va           Vari         10.492	Browse All	«			_					
Experiment Strategy       Q         #ritis       # 12,261 Files       \$ 863 Participants       \$ 804 Families       \$ 435.45 GB Size         Harmonized Data	Filters File	Filters	s			-		< :	share 🔯 Sa	ive
J WGS       1,969         Harmonized Data       I. 20         Any       Yee         J Weg       60 No         Data Category       Q         I File D       Participant       dbGap         Stengle Nucleotide Variation       5,948         I Konstantic Mutation       5,948         I Konstantic Mutation       1,899         I Karanticalis       5,948         I Karanticalis       9,848 <th>iment Strategy</th> <th>٩</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>-</th> <th></th> <th></th>	iment Strategy	٩						-		
Browing         Lit         Analyze in Cavatica         Download         Lit         File Manifesti         Columns           Harmonized Data         of         12,281         1         It         Analyze in Cavatica         Download         Lit         File Manifesti         Columns         It           Data Category         Q         File ID         Participant         dbCap         Study Code         Proband         Family Id         Diversion           Single Nucleotide Variation         5,948         OF_LISEPSZ         PT_CSANGE         PBTA-PNOC         Person         Quarts         Quarts           Data         6,313         GF_R08K0K         PT_TVUSEG         PBTA-PNOC         Yes         Value           Data Type         Q         GF_R08K0K         PT_TVUSEG         PBTA-PNOC         Yes         Value           Data Somatic Mutation         1,865         GF_R08K0K         PT_TVUSEG         PBTA-PNOC         Yes         Value           Somatic Structural Variations         825         Anotated Somatic Mutation         1,885         GF_R08K0R         PT_R5172255         PBTA-PNOC         Yes         Value           Somatic Structural Variations         825         GF_L08B12         PT_K00R0ME         PT_K00R0ME         Value <th></th> <th># FILES</th> <th></th> <th>12,261 Fil</th> <th>es 🏌 86</th> <th>3 Participants</th> <th>804 Fa</th> <th>milies 🛢</th> <th>435.45 GB s</th> <th>bize</th>		# FILES		12,261 Fil	es 🏌 86	3 Participants	804 Fa	milies 🛢	435.45 GB s	bize
Harmonized Data       1 - 20       0		1,969	Sł	owing		Deverte		- Marchines		ٹ Ex
Any       Yes       960       No       9.983       12,261         Data Category       Q       File ID       Participant       dbGap       Study Code       Proband       Family Id       Dr         Simple Nucleotide Variation       5.646       0.5182       PT_CSEHOB-       PartPNOC       Yes       Variant Calls         No Data       6.313       0.67       PT_RESAXQ-       PBTA-PNOC       Yes       Variant Calls         National Somatic Mutation       1.865       0.67       PT_VIJESC-       PBTA-PNOC       Yes       Variant Calls         Nonotated Somatic Mutation       1.865       0.67       PT_VIJESC-       PBTA-PNOC       Yes       Variant Calls         Somatic Structure Variant Call       7922       0.67       PT_VIJESC-       PBTA-PNOC       Yes       Variant Calls         Somatic Structure Variant Call       7922       0.67       PT_VIJESC-       PBTA-PNOC       Yes       Variant Calls         Somatic Structure Variant Call       7922       0.67       PT_RESCORE       PT_RESTZZES       PBTA-PNOC       Yes       Variant Calls       O.67       O.67       O.67       O.67       Variant Calls       O.67       O.67       O.67       O.67       O.67       O.67       O.67	onized Data		1	- 20	alyze in Cavatica	Downio	ad V 🕹 Fil	e Manifest	Columns	0
Data Category         Picks         File ID         Participant         dbGap         Study Code         Proband         Family Id         Dv           Simple Nucleotide Variation         6,313         0         6,2130         PT_CS8H08         PBTA-PNOC         Participant         Variant Calls         6,3133         Variant Calls         5,944         0         0         FT_CS8H08         PBTA-PNOC         Variant Calls         5,944         0         0         FT_CS8H08         PBTA-PNOC         Variant Calls         5,944         0         0         FT_CS8H08         PBTA-PNOC         Variant Calls         5,944         0         0         FT_CS8H08         PT_TX556         PBTA-PNOC         Variant Calls         5,944         0         0         FT         0         FT         0         FT         0         FT         Variant Calls         5,944         0         0         FT         0         FT         Variant Calls         5,944         0         0         FT         0         FT         0         FT         0         FT         0         0         FT	Yes 960	No 9,983	12	2,261						
FILES       9       91780PS22       PT_SEM08-       PBTA-PNOC       Value         Simple Nucleotide Variation       5,948       9       95.752       PT_SEGAXQ-       PBTA-PNOC       Value         Data       6,313       9       95.7058/08-       PT_SEGAXQ-       PBTA-PNOC       Value       Value         Data       6,313       9       95.7058/08-       PT_VISEG-       PBTA-PNOC       Ves       Value         Variant Calls       5,948       9       95.7058/08-       PT_VISEG-       PBTA-PNOC       Ves       Value         Variant Calls       5,948       9       95.7058/08-       PT_VISEG-       PBTA-PNOC       Ves       Value         Variant Calls       5,948       9       95.7058/08-       PT_VINAC-       PBTA-PNOC       Ves       Value         Variant Calls       5,948       9       95.7058/08-       PT_VINAC-       PBTA-PNOC       Ves       Value         Variant Calls       782       9       95.805808-       PT_REGASURE       PT_APROC       Ves       Value         Variant Call       782       9       95.40870-       PT_APROC       Ves       Value         0 3 More       9       95.40870-       PT_APROC       PS	atogory				Participant	dbGap	Study Code	Proband	Family Id	Data
Simple Nucleotide Variation     5,848 <ul> <li>gF. R02K01-</li> <li>PT. R66AXQ-</li> <li>PT. R66AXQ-</li> <li>PT. N02K0X-</li> <li>PT. N02K0X0X-</li> <li>PT. N02K0X0X0X0X-</li> <li>PT. N02K0X0X0X0X0X0X0X0X0X</li></ul>	Jategory									Varia
No Data       6,313         Data Type       Q         Jara Type       Q         Image: Spate	le Nucleotide Variatio									
Image: Notice of the second				GF_RD9K91	PT_RE6AXQ		PBTA-PNOC			Varia
Variant Calis     5,948       Variant Calis     5,948       Anotated Somatic Mutation     1,865       Masked Somatic Mutation     1,865       Asseed Somatic Mutation     1,865       Somatic Structure Variance     26       O Structure Variance     2782       O Structure Variance     95       Bornet Structure Variance     26       O Structure Variance     95       O Structure Variance     95 <t< td=""><td>Type</td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Type	0								
Variant Calls     5,948       Anotated Somatic Mutation     1,865       Masked Somatic Mutation     1,865       Somatic Structural Variations     1,819       Somatic Structural Variations     0       GE BQSDBB-     PT R572785       PBTA-PNOC     Ves       Variant Call     782       O 3 More     0       GE ATBEVG-     PT ADSURDES       Variant Call     0       File Format     0       GE JORDIZ-     PT ADSURDES       Variant Call     0       Structural Variant Call     0       GE JORDIZ-     PT ADSURDES       Partone     0       GE JORDIZ-     PT LESEGS-       PT 15850-     PBTA-PNOC       Variant Call     0       GE JORBEZ-     PT 158565-       Part APSURDES     PT 158565-				GF_NG6NGK	PT_TVJ5EG		PBTA-PNOC	Yes		Varia
Masked Somatic Mutation     1,819     Masked Somatic Mutation     1,819       Somatic Structural Variations     825     GF_B260BE-     PT_R5T725ES       Annotated Variant Call     782     GF_A1BYVG-     PT_A05JR0E5       File Format     Q     GF_A1BYVG-     PT_A05JR0E5       verf     12,261     GF_J02D12-     PT_KA0MYE-       tsv     5,187     GF_DR0825-     PT_153EGG-       bam     4,749     GF_DR0825-     PT_153EGG-	int Calls									
Masked Somatic Mutation 1819 Somatic Structural Variations 825 Annotated Variant Call 782 effer Format Q effer Format Q effer Somatic Structural Variations 825 effer Format Q effer Somatic Structural Variations 825 effer Somatic Struc	tated Somatic Mutati	on 1,865		OF REAAW2	DT VIHNAC		DRTA-DNOC			Varia
Protected Variant Call         782         GF B02088         PT R51728FS         PBTA-PNOC         Yes         Ya           0 3 More         0 GF A187YG         PT A05JR0E5         PBTA-PNOC         Yes         Ya           File Format         0         GF A187YG         PT A05JR0E5         PBTA-PNOC         Yes         Ya           Ver         13,261         0         GF J08022         PT A05JR0E5         PBTA-PNOC         Ya           Isw         5,187         0         GF J08022         PT 18560         PBTA-PNOC         Ya           Isam         4,749         0         GF J08022         PT 18560         PBTA-PNOC         Ya	ed Somatic Mutation	1,819		01_00/4112	FI_VIIIIAQ		FBIA-FILOC			varie
Anticalistic valuative	atic Structural Variatio	ns 825								
File Format         Q         PT_AD6JR0E5         PBTA-PNOC         Va           if 2,261         GE_JORD IZ         PT_KAGMYE         PBTA-PNOC         Va           10,492         GE_JORD IZ         PT_KAGMYE         PBTA-PNOC         Va           bam         4,749         GE_DR0825         PT_1E3E6G         PBTA-PNOC         Va	tated Variant Call	782		GF_BQ50BR	PT_R5T773FS		PBTA-PNOC	Yes		Varia
FILE Format         Q           #FILES         #FILES           10/092         0           tsv         5,187           bam         4,749		O 3 More								Valie
ver         12,261         OF_JQRD1Z_         PT_KAGMYE_         PBTA-PNOC         Va           10,492         0	ormat	Q	0	GF_A1BYVG	PT_A06JR0E5		PBTA-PNOC			Varia
10,492           tsv         5,187           bam         4,749         0 or DR9825           PT 1E3E8G           PBTA-PNOC	-	# FILES								
tsv 5,187 bam 4,749 G <u>F DR9825 PT 153F6G</u> PBTA-PNOC Va		12,261		GF_JQRD1Z	PT_KAQMYF		PBTA-PNOC			Varia
bam 4,749 GF_DR9825 PT_1E3E6G PBTA-PNOC Va		10,492								
bam 4,749		5,187	0	GE DR0825	PT 15256G		DBTA-DNOC			Varia
pdf 3.580		4,749	0	01_013020	<u>FI_1L3E00</u>		PDIA-PNOC			VOINE
		3,580								

Kids First @ Das	nboard 🖽 Stu	udies	糸 Explore Dat	a 🗏 Variant	□ File Repositor	ry 옷 Members							Resources ~	🕑 Renan 🗸
Clinical Filters	«		CLEAR FILE FORM	MAT is vcf × and S	TUDY NAME is	diatric Brain Tumor Atlas	X						≪ share	Save
Data Type	Q 4,009			10,879 Files		¥	804 Participants			804 Families		94	33.66 GB Size	
<ul> <li>Annotated Somatic Mutation</li> <li>Masked Somatic Mutation</li> </ul>	1,865	Sh	owing 1 - 20 of 10,	879 files					🔤 Analyze in C	Cavatica Downl	oad ~ 占 Fil	e Manifest	Columns 🗸 🛛 🛓	Export TSV
Annotated Variant Call	782		File ID	Participants ID	dbGap	Study Name	Study Code	Proband	Family Id	Data Type	Data Category	File Format	File Size	Actions
Somatic Structural Variation	• 782 • 3 More		<u>GF_VKQWPF16</u>	PT_VAJN5QP8		Pediatric Brain Tumor Atlas: CBTTC	PBTA-CBTN	Yes	FM_RDZVYSJH	Variant Calls	Simple Nucleotide Variation	vcf	889.54	KB
File Format	Q # FILES		<u>GF_3JT2W7K5</u>	PT_HMF8J4EG		Pediatric Brain Tumor Atlas: CBTTC	PBTA-CBTN	Yes	FM_96PFTQRJ	Annotated Variant Call		vcf	533.37 M	∕/B ♪
vcf maf	10,879 9,180		<u>GF_HKM5MD0V</u>	PT_FFRHWB74		Pediatric Brain Tumor Atlas: CBTTC	PBTA-CBTN	Yes	FM_GG0WCQY2	Masked Somatic Mutation		vcf	835.64	KB
) tsv ) bam ) pdf	5,027 4,484 3,548		<u>GF_7VW938AK</u>	PT_XTVQB9S4		Pediatric Brain Tumor Atlas: CBTTC	PBTA-CBTN	Yes	FM_8YZ1P1GY	Annotated Somatic Mutation		vcf	1.52 M	∕IB ▲
Family Shared Data Types	© 9 More		<u>GF_NQEAYVY2</u>	PT_HJMP6PH2		Pediatric Brain Tumor Atlas: CBTTC	PBTA-CBTN	Yes	FM_Y1SF4EM1	Variant Calls	Simple Nucleotide Variation	vcf	409.33	KB
Aligned Reads	# FILES		<u>GF_JH3P3V5W</u>	PT_WWME595X		Pediatric Brain Tumor Atlas: CBTTC	PBTA-CBTN	Yes	FM_Z9689EQQ	Variant Calls	Simple Nucleotide Variation	vcf	861.62	KB
Genome Aligned Read Annotated Variant Call	10,649 10,638	Sho	ow 20 v rows									<< <	1 2 3 4	5 > >>

Export TSV with file metadata for selected samples

to further select files to be analyzed in CAVATICA

### 

	Data Browser	
Projects	Public Reference Files	Q Search
PhenoDB Dev Project Created by:d3b-bixu · May 20, 2022, 15:3	Public Test Files	
Siealed by.usb-bixu • Way 20, 2022, 10.3	Volumes	
1000g_test Created by:renan.martin · Apr 28, 2022, 8	Data Tools	
R03	Datasets	

### KF X01 ODMS\_BEEC\_PHACE


Created by:cavatica · Jun 16, 2021, 13:57

### **KFDRC Sobreira Strelka2 Collab**

Created by:kids-first-drc · Dec 18, 2020, 11:57

### Genome-wide Sequencing to Identify the Genes Responsible for Enchondromatoses and Related Malignant Tumors

Created hyskide-firet-dro. May A 2020 13:40



#### All Member Admin

# Search PBTA-PNOC PBTA-CBTN MARIS\_NB\_XE\_01

MARIS\_NB\_CL\_01

SU2C\_MB\_PA\_01

MCGILL\_DIPG\_PA\_01

Chordoma Foundation Dataset

MEMBER PBTA-PNOC

Q

### DESCRIPTION


PNOC is an international consortium with study sites within the United States, Canada, Europe and Australia dedicated to bring new therapies to children and young adults with brain turnors. The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of over 22 children's hospitals that conduct clinical trials of new therapies for children with brain turnors. Our goal is to improve outcomes by translating the latest findings in cancer biology into better treatments for these children.

Patients with brain tumors that cannot be treated with standard therapy, or that have recurred following standard therapy, are often eligible for clinical trials. Clinical trials provide access to promising new treatments that may not be available outside specialized centers.

At PNOC, our focus is personalized medicine – testing new theraples that are specific to the biology of each patient's tumor to maximize their effectiveness. Our geal is to improve overall outcome for children with brain tumors.

### **Controlled Data Access**

For access to the BAM, FASTQ, CRAM files and Called Germline Variants, a data access request will need to be submitted at https://redcap.chop.edu/surveys/?s=A7/M873HMN8 and a signed Data Use Agreement(included on the Redcap form) will be required. Please email reserach@cbtn.org for additional details.



Files							
P Search							
Case ID: All 🔻	Sample	ID: All 🔻	Experime	ntal strategy: A	<b>₩ +</b>		
역 Copy 🕶							
□ <sup>1</sup> Name		Case	Sample ID	Sample ty	Primary s	Gender	Experimental
Narmo	nized-data	>	-	-	-	-	-
🗆 🖿 source	-data	-	-	-		•	-
Files							
Q	Search						
Ca	se ID: All 🔻	Sample ID: A	All - Experim	ental strategy: All 🕶	+		
P	Copy -						

Single gene pathogenic variants associated with BEEC (Bladder extrophy, Epispadias, Complex)

Search projects

PhenoDB Dev Project

KF X01 ODMS BEEC PHACE

KFDRC Sobreira Strelka2 Collab

Projects

1000g\_test R03 Q

## Ollier disease and Maffucci syndrome BHCMG-CMG Program - AnVIL

Access germline WES data from 33 probands with Ollier disease and Maffucci syndrome




# To be accessed



### The AnVIL

The AnVIL supports the management, analysis and sharing of human disease data for the research community and aims to advance basic understanding of the genetic basis of complex traits and accelerate discovery and development of therapies, diagnostic tests, and other technologies for diseases like cancer. The data commons supports cross-project analyses by harmonizing data from different projects through the collaborative development of a data dictionary, providing an API for data queries and download, and providing a cloud-based analysis workspace with rich tools and resources.



Submit Data 🐧



C gen3.theanvil.io/explorer			ů 🖈 🗯 🖬 🚯	1	
		Submit Data 土 💧	Documentation rmart120 (2) Logout	Ð	
The AnVIL		[] Dictionary	الله الله الله الله الله الله الله الله		
ata File Downloadable		Explorer Filters   Data T	ools   Summary Statistics   Table of Record	Is	
ta Access $\land$	Export to Seven Bridges 😧 Export All to Terra 🕫 🕒 Export to PFB 🛓	은 Export to Workspace 🛓			
Data with Access     Data without Access     All Data	Subjects <b>3,202</b>	Proje 1	cts		
ers	SexFemale	Ancest	Export to Sev	ven Bridges Export	All to Terra 🖸
rojects Subject X Sample X Sequencing ollapse all ~ Project Id 1 selected × @ Q	л.271 (39.7%) Маle	$\mathbf{D}$	Ex	port to CGC 🛛	Subjects
open_access-1000Genomes 3,202     tutorial-synthetic_data_set_1 2,504	1,233 (38.5%)		Ехро	rt to CAVATICA 🛛 🖓	3,202
Anvil Project Id	no data 698 (21.8%)		Export to E	BDC (Seven Bridges) 🛛	
no data 3,202					Sex
∨ Project dbGaP Accession Number	Showing 1 - 20 of 3,202 subjects Show Empty Columns			Female	
open 3,202	Project Id Sex Samples Count Sequencings Count				



You are about to import data from Gen3 **anvil** as DRS files with associated metadata. The data will be imported via PFB file. Learn more




Skip 🕶

Add tags Type to search...

 I understand that data accessible via DRS, including but not limited to controlledaccess data, may be subject to terms and conditions of acceptable use, and I confirm that I am only importing data in accordance with any applicable terms of use, including but not limited to my obligations under any applicable Data Use Agreements. Furthermore, I understand that I am importing a PFB file which may contain controlled access data and I confirm that I am solely responsible for managing access to this file since no other mechanisms protect this file in any way and the data could be accessed by other users in this project.

Destination project




 I understand that data accessible via DRS, including but not limited to controlledaccess data, may be subject to terms and conditions of acceptable use, and I confirm that I am only importing data in accordance with any applicable terms of use, including but not limited to my obligations under any applicable Data Use Agreements. Furthermore, I understand that I am importing a PFB file which may contain controlled access data and I confirm that I am solely responsible for managing access to this file since no other mechanisms protect this file in any way and the data could be accessed by other users in this project.



Impo

© 2022 Seven Bridges Genomics

Terms Privacy Copyright



$\leftrightarrow$ $\rightarrow$ C $$ cavatica.sbgenomics.com/u/renan.martin/1000g-test	t/files/#q						ů 🖈 🖈 🗖 🖪	
CAVATICA Projects - Data - Public Apps F	Public Projects	Developer 👻 Con	trolled projects				🌲 👻 renan.mar	tin •
Dashboard Files Apps Tasks			1000g_test @	6			Interactive Analysis Settings No	tes
Files  Search  Extension: All  Sample I	D: All 🔻 Task I	ID: All 👻 Tags: All 🕶	+ Clear filters				New folder + Add files	
□ ▼ Name	Extension	Reference genome	Primary site	Disease type	Kids First Family ID	Kids First Biospecimen ID	Kids First Participant ID	•
BRS NA18567.haplotypeCalls.er.raw.g.vcf.gz	VCF.GZ		-	-		-	-	
DRS HG02127.final.cram	CRAM		~	-			÷	
DRS HG04019.final.cram	CRAM	i.e.		-			-	
DRS HG01840.final.cram	CRAM	72	-	8	2013 2013	2	2	
DRS HG01138.haplotypeCalls.er.raw.vcf.gz.tbi	ТВІ	-	-	-	-	-	-	
DRS NA18876.final.cram.crai	CRAI	5. 20				÷		
DRS HG00234.haplotypeCalls.er.raw.g.vcf.gz.tbi	ТВІ	3 <b>x</b> .	×	-				
BRS HG04061.final.cram.crai	CRAI	1. <b></b> .		-	.*.)			
g DRS HG00323.final.cram.crai	CRAI	·	-	1	3	New York		
DRS HG00332.haplotypeCalls.er.raw.g.vcf.gz.tbi	ТВІ	æ	-	-	1 <u>21</u>		-	
DRS HG01167.final.cram.cral	CRAI		~	-				
DRS HG01523.haplotypeCalls.er.raw.vcf.gz	VCF.GZ	12	-	-	2	2	2	
C Refresh	CD MM						Showing 1-100 of 13010 < >	4

Then, the AVRO file will be replaced by imported files once import finishes

## **Next Steps**

Access Ollier disease and Maffucci syndrome files from BHCMG with CAVATICA

• Once the access on AnVIL/Gen3 is granted, we will be able to export (access) to CAVATICA via Seven Bridges (function already tested with open datasets)

Access chondrosarcoma files from NCI GDC Portal with CAVATICA

# Acknowledgments

- Nara Sobreira' lab
- Renan Martin
- Elizabeth Wohler
- Eliete Rodrigues
- Corina Antonescu
- Carolina Montano
- □ Kim Doheny
- Sean Griffith
- Laura Vail

### NIH - NCPI

- Asiyah Lin
- □ Seven Bridges
- Jack Digiovanna
- □ NIH NCI
- Jay Ronquillo
- Erika Kim
- Broad Institute
- Ruchi Munshi
- Rachel Liao

### □ Funding - NIH – NHGRI and NCI



# NCPI Working Group Updates



## 11:50 AM - 1:05 PM EDT

# Community Governance WG

## Bob Grossman (University of Chicago) Stanley Ahalt (University of North Carolina at Chapel Hill)

## General Framework

- The NCPI Community / Governance Working Group is not charged with coming up with specific policies or recommendations.
- Instead, this group is charged with coming up with
  - associated use cases and questions that help frame the fundamental governance questions;
  - concepts and frameworks to support interoperability for the use cases;
  - Key questions for the community consensus.
- We summarize the key questions, associated frameworks, and community consensus in technical papers.


Phase 1 - Viewing NCPI Platforms following NIST 800-53 (or other approved frameworks) as Authorized Environments

Key Concepts

**Project Sponsor** - Entity responsible for data and platform governance.

**Right to distribute** - the project sponsor determines whether the source cloud platform has the right to distribute a particular dataset


Authorized environment - the project sponsor determines whether the target cloud platform has appropriate security, compliance and governance to support the analysis of the data on the cloud platform by authorized researches




Cloud Platform A boundary



Cloud platform portal





Cloud Platform B boundary

- 1. The **Project Sponsor** sets up and operates frameworks for 1) data governance and 2) platform governance.
- 2. A cloud platform A has the **right to distribute** a particular dataset.
- 3. A cloud platform B is approved as **authorized environment** for a particular dataset.

Workspace for user

Security and compliance boundary



### Computer Science > Distributed, Paranel, and Cluster C

[Submitted on 10 Mar 2022]

### A Framework for the Interoperability of Cloud Platforms: Towards FAIR Data in SAFE Environments

Robert L. Grossman, Rebecca R. Boyles, Brandi N. Davis-Dusenbery, Amanda Haddock, Allison P. Heath, Brian D. O'Connor, Adam C. Resnick, Deanne M. Taylor, Stan Ahalt

As the number of cloud platforms supporting biomedical research grows, there is an increasing need to support interoperability between two or more cloud platforms. A well accepted core concept is to make data in cloud platforms findable, accessible, interoperable and reusable (FAIR). We introduce a companion concept that applies to cloud-based computing environments that we call a Secure and Authorized FAIR Environment (SAFE). SAFE environments require data and platform governance structures. A SAFE environment is a cloud platform that has been approved through a defined data and platform governance process as authorized to hold data from another cloud platform and exposes appropriate APIs for the two platforms to interoperate.

Comments:11 pages with 1 figure and a 2 page appendixSubjects:Distributed, Parallel, and Cluster Computing (cs.DC)ACM classes:D.2.11; D.2.12; E.0Cite as:arXiv:2203.05097 [cs.DC]<br/>(or arXiv:2203.05097v1 [cs.DC] for this version)<br/>https://doi.org/10.48550/arXiv.2203.05097 1

## Status

- Community consensus and agreement on key concepts and framework
- Technical paper completed and published on arXiv
- Selected interoperability approved for selected datasets between pairs of NCPI Cloud Platforms
- No general guidelines yet about interoperability between 2 or more NCPI Platforms

## Potential Next Steps


- Seek approval for the current NCPI Platforms as authorized environments for data from one of the other NCPI Platforms.
- Seek approval for selected other platforms that follow NIST 800-53 Moderate as authorized environments for one or more NCPI platforms.

# Phase 2 - Interop for Low Sensitivity Data

# Basic Idea

- Not all data in current NCPI platforms are equally sensitive
- Today, controlled access genomic data is classified is usually housed in cloud platforms that FISMA Moderate.
- For less sensitive data, such as as certain aggregate or summary data level data, perhaps we can classify as less sensitive (call it low sensitivity) data and approved in cloud platforms that are are FISMA Low or approved for CUI, for example.

Overview interop with low sensitivity data




**Cloud Platform A boundary** 



Cloud platform portal

Cloud platform boundary



Cloud Platform B boundary

- 1. The **Project Sponsor** sets up and operates frameworks for 1) data governance and 2) platform governance.
- 2. Data D has low sensitivity.
- 3. A cloud platform A has the **right to distribute** data that is **low sensitivity**
- 4. A cloud platform B is approved as **authorized environment** for **low sensitivity data.**

Workspace for user

Security and compliance boundary

# Controlled Unclassified Information (CUI)

NIST Special Publication 800-171 Revision 2


Protecting Controlled Unclassified Information in Nonfederal Systems and Organizations

> RON ROSS VICTORIA PILLITTERI KELLEY DEMPSEY MARK RIDDLE GARY GUISSANIE

• CUI

- Follows NIST 800-171
- Can be used for less sensitive data


A very simple use case of low sensitivity data being generated by applying approved workflows to genomic data.



### Questions

- If there is a data or security incident, when data is transferred from one cloud platform to another, who is responsible when there is a security or data management event or incident?
  - The platform that receives the data?
  - As determined by the platform sponsor?
  - As determined by the Interconnection Security Agreement?
  - The platform that sends the data?
  - It depends upon the specifics of the event or incident?
  - In practice, it depends upon whether the sponsor of the target platform is another Institute or Center?
  - Some combination of the above?
- Answering these questions conservatively, has essentially slowed down access to the data by the research community from cloud platforms, despite the fact that the current cloud platforms tend to operate under higher levels of security and compliance.

### **Evaluating Risks**



- The Open Web Application Security Project (OWASP) is an online community that produces freely-available articles, methodologies, documentation, tools, and technologies in the field of web application security. The Open Web Application Security Project provides free and open resources.
- NIST 800-30 also provides framework
- and several others are widely used

Sources: https://owasp.org/www-community/OWASP\_Risk\_Rating\_Methodology

### Risk

risk = risk impact \* likelihood of risk

- Impact (also called risk impact) defines 'how bad' things can get, the worst-case scenario. Impact is primarily based upon the data.
- Likelihood defines the probable frequency, or rate at which the impacts we assessed may occur. Likelihood on the other hand is primarily driven by the presence or absence of security controls in the service.

Sources: https://owasp.org/www-community/OWASP\_Risk\_Rating\_Methodology

https://infosec.mozilla.org/guidelines/assessing\_security\_risk

### Some Risks

1. Honest but curious person downloads the data and exposes it through unintentional misuse.

2. Uses unsigned code that's a "look alike" docker that exfils the data

- 3. Data is modified through a bug and not detected
- 4. Other risks....

Sources: David Bernick email, discussion in previous NCPI Community / Governance WG call

### Risks in the Context of Use Case 1

#	Risk	Use Case 1	Comment
1	Honest but curious person downloads the data and exposes it through unintentional misuse.	Data is aggregated sufficiently that risk of re-identification is quite low	
2	Uses unsigned code that's a "look alike" docker (like what's happening with NPM libraries now and supply chains) that exfils the data	Workflow is signed and data platform service executes workflow (vs user executing workflow)	
3	Data is modified through a bug and not detected	Risk is present whether data is analyzed in Platform A or egressed to Platform B	
4	Other risks		

### **Questions / Discussion**

# Systems Interoperation WG



Jack DiGiovanna (Seven Bridges)

Why is interoperability important for NIH?



Bic	chimica et Biophysica Acta on Cancer Volume 1876, Issue 1, August 202	1
The pote	ential of AI in cancer	care and
research		
Norman E. Sharple	s M.D. 온, Anthony R. Kerlavage Ph.D.	
Show more 🗸		
+ Add to Mend	eley 🗠 Share 🍠 Cite	
https://doi.org/10.1	016/j.bbcan.2021.188573	Get rights and content
Abstract		
learning in car	ations of artificial intelligence (A neer research and clinical care are	highly diverse—from aiding


Current applications of artificial intelligence (AI), machine learning, and deep learning in cancer research and clinical care are highly diverse—from aiding radiologists in reading medical images to predicting <u>oncoprotein</u> folding and dynamics. The list of available AI-based tools is growing rapidly and will only continue to expand. With the immense potential for AI to advance cancer

#### Image credit: https://www.sciencedirect.com/science/article/abs/pii/S030441 9X21000706




### Empower diverse researchers to complete scientific projects across ICs by spearheading technical improvements across cloud "stacks"

Valentina Di Francesco (NHGRI) & Ken Wiley (NHGRI)	
Stanley Ahalt (RENCI) & Bob Grossman (UChicago)	
<b>Brian O'Connor</b> (Sage Bionetworks) & Jack DiGiovanna (Seven Bridges)	
Stephen Mosher (JHU)	
Robert Carroll (Vanderbilt) & Allison Heath (CHOP)	
Dave Rogers (Clever Canary) & Kathy Reinold (Broad)	



### Helps users analyze scientifically-relevant data








genomic DNA and then reverse transcribing a new LINE-1 DNA copy into that breakpoint. In most contexts, LINE-1 elements are epigenetically repressed, but they are dramatically





### NCPI is trailblazing interoperability policy as well





### **Together we've made it easier for the next researcher**

### Agreed on a finite set of technical methods

#### Manifests (PFB or CSV) **Object access** Access method i213 compactIDs pr369 Attribute Definition C **Global Allia** who AuthZ pr381 for Genomics DRS URI as defined by GA4GH DRS spec for pointers to file objects. drs uri C External source from which the identifier included in study\_id originates name\* i335 tt study\_registration (answer can be dbGaP for example) **Data Repository Se** study\_id Unique identifier that can be used to retrieve more information for a study develop branch status: build passing DOI 10.5281/zenodo.1405753 Unique identifier that can be used to retrieve more information for a σ participant id participant Ū AuthN/Z Unique identifier that can be used to retrieve more information for a 70 specimen id specimen Collaborating with NIH RAS experimental strate The experimental strategy used to generate the data file referred to by the NIH RAS is a unified, efficient, and secure authentication and authorization ser Establishing *N* mTLS certs streamlined researcher access to NIH-funded data assets and data repositories a ga4gh drs uri. (Based on GDC definition) of logging and auditing such access gy for N servers The format of the data, see possible values from the data format fields in Internal NIH Researchen Log in with NIH credentials A GDC. Can use whatever values make sense for the particular Challenge: *N* user passports • file format implementation. NIH RAS Login for N servers fhir document refer optional fhir url pointing to the FHIR Document Reference, if metadata External Researchers on in with prefer available on a FHIR Server ence Ω OGIN GO The name of the file the DRS URI is pointing to. file name Identity Brokerto provide a unifie Integrate account information from efficient and secure authentication, authorization and auditing mechani multiple platforms

NIH Researcher Auth Service 1.0: Conceptual Overview



### All use cases require a one-pager on a **public github repo**

Ensure that the this info is **agreed** upon:

- Platforms Involved
- Scientific question
- Science Lead & Platform Lead
- Interop/Tech Plan
- Funding Plan

Search or jump to 7 Pull requests Issues Marketplace Explore			4 +· 💽
NCPI Use Case Tracker			• •••
HI AII 💿 🗄 Interop 🖽 Search 🖽 FHIR + New view			Beta Give feedback
· Title	Assignees	Status	Labels
1 💿 UC 1a. Develop a more accurate pipeline to detect de novo mutations in family trios by utilizing the c			SYS INTEROP
2 🕟 UC 1b. Genetic Basis of Congenital Heart Defects (Goldmuntz)	NoopDog ~	Training Material Dev -	dissemination phase SYS INTEROP
3 💿 UC - 5. LINE-1 Retrotransposon Expression	🚇 NoopDog 🛛 👻	Training Material Dev 👻	dissemination phase SYS INTEROP
4 O UC 7. Genetic factors related to congenital heart defects (Manning)	🚇 NoopDog 🛛 👻	Training Material Dev -	dissemination phase SYS INTEROP
5 💿 UC 8. PIC-SURE API search of clinical and genomic data available from Seven Bridges Platform	💈 jackDiGi 🚽 🗸	Needs One Pager	SEARCH SYS INTEROP
6 O UC 9. Whole slide images		Needs One Pager	SYS INTEROP
7 💿 UC 10. SRA & Kids First DRC for Kids First & UDN co-analysis	🍻 jackDiGi and mat -	Ready to Develop	SYS INTEROP
8 💿 UC 11. Sex as a Biological Variable (Wilson)	🍘 briandoconnor a -	Training Material Dev -	SYS INTEROP
9 💿 UC 12 - (Xihong) Whole Genome Sequencing Association Analysis pipeline			SYS INTEROP
10 🕟 UC 13: Leverage functionally equivalent pipelines for long-reads data on different systems	🎒 jackDiGi and Noc –	Ready to Develop -	SYS INTEROP -
11 💿 UC14. Genome-wide Sequencing Analysis to Identify the Genes Responsible for Enchondromatoses a			SYS INTEROP
12 💿 UC15. Using the NCI Cancer Research Data Commons and NHLBI BioData Catalyst to better understa	🍈 jay-nih 🚽		SYS INTEROP
13 ③ FHIR UC1: ResearchStudies representation in rare disease (CMGs & Kids First)	🎲 liberaliscomputir -	Needs One Pager	FHIR
14 O FHIR UC3: UDN phenotype structuring in FHIR for Kids First interoperability	🧑 adeslatt 🚽	Needs One Pager -	(FHIR)

Credit to Dave Rogers and Asiyah Lin

https://github.com/orgs/NIH-NCPI/projects/1/views/6




# Sex chromosome complement aware alignment

Brendan Pinto and Melissa Wilson

Genome-wide Sequencing Analysis to Identify the Genes Responsible for Enchondromatoses and Related Malignant Tumors

Renan Martin Nara Sobreira Johns Hopkins University School of Medicine







Thank you for NIH ODSS's support and partnership for NCPI

*Reusing* developed components, *improving* the "use-case" process, and the *community helping* each other will **increase speed to results** 

Researchers can analyze select CRDC, TOPMed, Kids First, and AnVIL data

Want to **build awareness & adoption to grow the ecosystem**; also need to optimize **strategy** - please connect us with the latest **researcher challenges** 


Learn more @ https://anvilproject.org/ncpi







# FHIR WG



Robert Carroll (Vanderbilt University Medical Center) Allison Heath (Children's Hospital of Philadelphia)

### Overview


- Objectives for FHIR
- FHIR Service Deployment
- FHIR Implementation Guide v0.1 Complete
- Refactoring our approach- IG v0.2
- FHIR Code-a-thon next week!

# **Objectives of FHIR**

- 1. To provide an API to allow access to study and participant level data.
- 2. To provide standardized structures for study and participant data.
- 3. To enable structured semantics for data where available.

While there are solutions to some of these problems across NCPI, FHIR is an international standard with broad support across academics and vendors (including cloud providers) that provides methods to address all of them.

# **Objectives of FHIR**



# FHIR Service Deployment

### Formal NCPI Teams





National Library of Medicine National Center for Biotechnology Information




- Kids First: Production FHIR Services deployed
  - <u>https://kf-api-fhir-service.kidsfirstdrc.org/</u>
  - Open access data, requires login to KF Portal
- dbGaP: Public data services deployed
  - <u>https://dbgap-api.ncbi.nlm.nih.gov/fhir/x1/</u>
  - Study level data only
  - Work in progress on controlled access data, pilot implementations complete
- AnVIL: Non-production service pilots
  - Test deployment indexing AnVIL data across Terra
  - Pilot study specific ETL
- Highlighted community groups
  - ImmPort: <u>Developed IG</u> and have deployed services, includes dev service: <u>https://fhir.dev.immport.org/</u>
  - INCLUDE DCC: Production FHIR service with registered user data access: <u>https://include-api-fhir-service.includedcc.org/</u>






# Implementation Guide v0.1

- Github:
  - https://github.com/NIH-NCPI/ncpi-fhir-ig
- Pages: <u>https://nih-ncpi.github.io/ncpi-fhir-ig/</u>
- Originally published in 2021, focused on rare disease modeling for genomic research
- Live deployments have generated valuable feedback
  - Broader use cases
  - Refining approach to asserting semantics




# Interoperable Data Services


- The vision for FHIR across NCPI is to provide a set of services for the data and metadata to empower researchers.
- Not all services apply to all datasets nor platforms, but many are common!



# Interoperable Data Services

- We are re-organizing into a set of modules or services that help make clear what is being provided.
- This slide has a rough sense of some use cases.





Research Study Metadata				
Study	Data			
Information	Dictionaries			
Consent	Variable			
Groups	Reports			

'Omics data	DRS References
Genomic	File
Assays	Metadata

# IG v0.2

- This reorganization will make the underlying objective of the IG more clear
- Additionally, documentation will be more accessible to implementers and users of the NCPI FHIR services
- Use cases will be better integrated as well, with guides to users to help understand what services may be offered and how that may impact their analyses.

# FHIR Code-a-thon

- Last summer, support from the ODSS enabled us to host a general purpose FHIR training for the NCPI community.
- Next week, 27 and 28 June 2022, we are hosting another event!
- We will implement an end-to-end analysis using a suite of NCPI-supported standards and tools, including FHIR and DRS.
- We will analyze RNASeq-derived Gene Expression data, with the primary target of clustering samples by gene expression.
- We hope to show the power of the work many of you have contributed!

## FHIR Code-a-thon

- Event Overview: NCPI FHIR Code-a-thon 27-28 June 2022
- <u>Registration Link</u>
- <u>Github Repository</u> for managing shared code
- <u>Github Project</u> for tracking event status

- There are opportunities to contribute across technical, scientific, and documentation domains; please drop in if you are able.
- If you can't make it this week, the code and access information may help you get started in the future!


# NCPI Outreach WG



Stephen Mosher (Johns Hopkins University)


To prevent the development of siloed platforms by providing unified access to key information and training resources associated with each NCPI platform.

- Develop and maintain NCPI Portal
- Aggregation of platform-related outreach and training materials
- Document commonly used resources
- Maintain a catalogue of NCPI datasets
- Support NCPI Workshops



## NCPI Portal

### https://anvilproject.org/ncpi



#### Team


The NCPI is a collaboration between NIH representatives, platform team members, and researchers running

### **Participating platforms**

NIH Cloud Platform		
NCPI Interoperability Effort	Q Search	0 0
	Overview Platforms Technologies Datasets Demonstration Projects	Training Upda
Overview	Overview of Participating Platforms	On This Page
BioData Catalyst	NHGRI AnVIL	NHGRI AnVIL NHLBI BioData Cataly
CRDC Kids First	https://anviiproject.org	NCI Cancer Research Data Commons (CRD)
NCBI	🕊 @useAnVIL 💶	NIH Common Fund - I First Data Resource
	The NHORI Genomic Data Science Analysis, Visualization, and Informatics Lab-space, or AnVIL, is NHORI's genomic data resource that leverages a cloud-based infrastructure for democratizing genomic data access, sharing, and computing across large genomic, and genomic-related data sets.	National Center for Biotechnology Information (NCBI) at
	In addition to downloading copies of data to local computers and servers, users will have the option to work, with data in a secure cloud environment, where they can also use common bioinformatics tools and packages and develop and share their own software tools. Learn more about AnYIL.	National Library of Medicine (NLM)
	NHLBI BioData Catalyst	
	https://biodatacatalyst.nhlbi.nih.gov	
	ש #BioDataCatalyst	
	NH.BI BioData Catalyst is a cloud-based platform providing tools, applications, and workflows in secure workspaces. By increasing access to NH.BI datasets and innovative data analysis capabilities, BioData Catalyst accelerates efficient biomedical research that drives discovery and scientific advancement, leading to novel diagnosti colos, therapeucics, and prevention strategies for heart, lung, blood, and sleep disorders.	
	Though the primary goal of the BioData Catalyst project is to build a data science ecosystem, at its core, this is a people-centric endeavor. BioData Catalyst is also building a community of practice working collaboratively to solve technical and scientific challenges. Learn more about BioData Catalyst.	
	NCI Cancer Research Data Commons (CRDC)	
	https://datacommons.cancer.gov	
	9 #NCICommons @genomicscloud @BroadFireCloud @isb_cgc •	
	The goal of the National Cancer institute's Cancer Research Data Commons (CRDC) is to empower researchers to accelerate data-driven scientific discovery by connecting driverse datasets with analytical tools in the cloud. The CRDC is built upon an expandable data science infrastructure that provides secure access to many different data across scientific domains via Data Commons Framework.	
	The CRDC enables users to search and aggregate data across repositories via the Cancer Data Aggregator	

## NCPI Portal

### **Technologies enabling science**




### The science driving the tech

NIH Cloud Platform Interoperability Effort				Q Searc	h		O	0
		Overview	Platforms	Technologies	Datasets	Demonstration Projects	Training	Upda
NCPI Interop Demonstration Projects	NCPI Interope	rability	Demon	stration l	Project	S	On This Page	
Control Easis of Congenital Heart Detects (Goldmunts) LINE-1 Retrotranspoon Expression (McKerrov) Genetic Factors Related to Congenital Heart Defects (Muanning) Sex as Biological Variable (Witson)	The NCPI interoperabilit exercise specific scienti Feedback from the proje requirements and valida The following demonstration j and results as they become at Genetic Bases of CC Platforms - NHLBI BioData C In this research, we intend to analysis approaches, machine heip fill in the gapt that exist is community to better understa whole-genome sequence dat LINE-11 Retrotransp. Platforms - AnVIL + CRDC This interoperability project al progressing and also combinat request from our users, so fin	ic and technik tots is used to te the utility of arojects are uncalled on generated in a second atalayst + Kids F study the gene learning meth atalayst + Kids F study the gene learning meth and cardiogene a will facilitate of oson Expr ms to find a pa ion with a prior	al use cases aid the disco f the develope der develope methods and the develope irst DRC tic bases of coro diding of the etil is and to bette our work. Read ession (M th to connect th analysis on the	related to cloud- very of detailed id d features. at and will be updi eccts (Goldm regenital heart defi ther statistical an oboyor OFDs. The research of the ckerrow) the GTEx data on tt c CRE. This "nor	platform int Interoperabil atted with deta untz) ects using var g genetic ana is will help this is will help this f disease. Ac	eroperability. Ity alis on methods iant and gene set Hysis models to e scientific ecess to this	Genetic Base Congenital H (Goldmust) Expression (Goldmust) Genetic Base Congenital H (Marning) Sex as a Biotic With Variable (With	eart Defec ransposor AcKerrow) s of eart Defec ogical
	Genetic Bases of Co	ongenital I	Heart Defe	ects (Manni	ng)			
	Platforms - NHGRI AnVIL + K				ts in a study (	design that uses		

Sex as a Biological Variable (Wilson)

## NCPI Portal

### Aggregating outreach resources




### Past workshop resources

□ - < >	D 👌 (B	-	anvilproject.org		0		Ć	) +	5
NIH Cloud Platform Interoperability Effort				Q, Searc	1		0	0	
		Overview	Platforms	Technologies	Datasets	Demonstration Projects	Training	Upda	at
Updates	Progress Upda	ites					On This Page		
	The NCPI holds worksho progress updates and d					vide	5th NCPI Wor October 5, 20 4th NCPI Wor May 3rd, 202	21 kshop -	
	5th NCPI Workshop	- October	- 5, 2021				3rd NCPI Wor October 30th 2nd NCPI Wo	kshop - . 2020 kshop -	
	Overview						April 16, 2020 1st NCPI Worl October 03, 2	shop -	
	Agenda     Presentation Slides								
	AM Video (1:57)								
	• PM <u>Video</u> (1:27) Day 2 ବ୍ତ								
	<ul> <li>AM Video (2:13)</li> <li>PM Video (2:02)</li> </ul>								
	4th NCPI Workshop	- May 3rc	l, 2021						
	Overview <ul> <li>Agenda</li> </ul>								
	Day 1								
	Video (3:15)     Presentation Slides								
	Meeting Summary Day 2								
	Video (3:22)     Presentation Slides								

## NCPI Dataset Catalog









<u>Data Repository Service</u>



<u>F</u>ast <u>H</u>ealthcare <u>I</u>nteroperability <u>R</u>esources

12Pb / 830k participants and growing! Cross-platform accessibility through several key technologies

## Dataset Search (more details from Search WG)

	ata   NCPI	× +								
$\leftrightarrow$ $\rightarrow$ C $$ anvi	ilproject.org/ncp	i/data							Q &	* 🛯
Apps 🔢 🛅 JH HR	R 🗎 AnVIL 🧃	🛨 🕉 🔿 🐻 🛆 AnVII	🛆 GDSCN	🔺 Galaxy 📑 QWGU 🗎 (	GDSCN	🗎 Galaxy 🗎 Workshop	os 🗎 Image	s 🗎 Learn	»	Reading
NIH Cloud Interopera	Platform ability Effort					Q Search			o	0 #
				Overview Platforms	Te	chnologies Datasets	Demonstra	tion Projects	Training	Updates
	at Catal									opaatoo
NCPI Datas	et Catal	og								
Search										
e.g. disease, study name,	dbGaP Id									
Platform		Focus / Disease		Data Type		Study Design		Consent Code		
AnVIL	45	Alzheimer Disease	2	Allele-Specific Expression	1	Case Set	36	ALZ		1
BDC	113	Anemia, Sickle Cell	10	AMPLICON	1	Case-Control	29	ALZ_NPU		1
CRDC	28	Arterial Pressure	2	Bisulfite-Seq	5	Clinical Trial	7	ARR		1
KFDRC	17	Asthma	17	ChIP-Seq	3	Control Set	3	DS-AF-IRB-F	2D	2
		+ 59 more		+ 20 more		+ 6 more		+ 119 more		
No selected terms.										
Download TSV 🛃 Co	opy URL 🔲									
Search Summa	arv									
Platform				Stu	dies					Participants
AnVIL				310	45					312.933

AnVIL	45	312,933
BDC	113	438,041
CRDC	28	97,122
KFDRC	17	14,984
Totals *	191	830,805

#### Search Results

Platform	Study	dbGap Id	Focus / Disease	Data Type	Study Design	Consent Code	Participants
AnVIL	A Genomic Atlas of Systemic Interindividual Epigenetic Variation in Humans (GTEx)	phs001746	Reference Values	Bisulfite-Seq	Control Set	GRU	194
AnVIL	Autism Sequencing Consortium (ASC)	phs000298	-	SNP/CNV Genotypes (NGS), WXS	Case-Control	DS-ASD, GRU, DS-AOND- MDS, HMB-MDS	12,772

### Search by:

- Platform
- Focus or Disease
- Data type
- Study Design
- Consent Code

Budded off into new Search Working Group

## Dockstore Organization for NCPI


Promoting FAIR practices in tool and workflow sharing

- Findable
- Accessible
- Interoperable
- Reusable

Occkstore   Organization x +	٥
← → C       dockstore.org/organizations/NCPI	🖈 😕 😫
🔢 Apps 🔟 📄 JH HR 🚞 AnVIL 🛨 🧬 闪 🔯 🛆 AnVIL 🛆 GDSCN 🙆 Gal	axy 📄 QWGU 🛅 GDSCN 🛅 Galaxy 🛅 Workshops 🛅 Images 🧼 🛅 Reading List
Construction Construction Construction Construction	Docs EForum Login Register
Constant / NIH Cloud Platform Interoperability Effort	
NIH Cloud Platform Interopera The NIH Cloud Platform Interoperability Effort (NCPI) will establish a analyses across participating cloud platforms.	bility Effort Transform Tr
Collections 1 and Members 3 C Updates 10	About the Organization
💠 AnVIL, Kids First, & BioData Catalyst	GD https://anvilproject.org/ncpi
Investigate genetic factors related to congenital heart defects in a study	About
design that uses healthy controls from two NHLBI cohorts. Perform pooled analysis on AnVIL powered by Terra.	The NIH Cloud Platform Interoperability Effort (NCPI) will establish and implement
	guidelines and technical standards to empower end-user analyses across participating
View	cloud platforms and facilitate the realization of a trans-NIH, federated data ecosystem.
	Participating Platforms
	NHGRI AnVIL
	NHLBI BioData Catalyst
	Cancer Research Data Commons
	Kids First Data Resource Center
	National Center for Biotechnology Information
	Interoperability Demonstration Projects
	This effort is guided by several cross-platform demonstration efforts. Feedback from the
	research efforts is used to aid the discovery of detailed interoperability requirements and
	validate the utility of the developed features.
	There are currently six cross-platform demonstration efforts:

## Supporting NCPI Workshops

Workshop	Date	Host
1st NCPI Workshop	03-04 October, 2019	BioData Catalyst
2nd NCPI Workshop	16 April, 2020	AnVIL
3rd NCPI Workshop	30 October, 2020	Kids First
4th NCPI Workshop	3-4 May, 2021	BioData Catalyst
5th NCPI Workshop	5-6 October, 2021	NCI CCDH
6th NCPI Workshop	22-23 June, 2022	AnVIL




## Today's Virtual Workshop

- Dedication from the Outreach WG, wider NCPI community and our partners to make today's event possible
- Planning across two days, four sessions of speakers, two breakout sessions, one panel discussion
  - 19 Speakers, 15 Breakout Moderators, 8
     Note Takers, 3 Panelists, two MCs
  - 175 Registered Participants



	Session	Candidate 1	Candidate 2	Note taker
	Parallel Session 1	Allison Heath	Brian O'Connor	Beth Sheets
DAY1	Parallel Session 2	Valentina Di Francesco	Mike Feolo	Natalie Kucher
2-4pm EDT	Parallel Session 3	Chris Wellington	Stan Ahalt	David Higgins
22JUN2022	Parallel Session 4	Kathy Reinold	Adam Resnick	Marcia Fournier
	Parallel Session 5	Michael Schatz	Rachel Liao	Stephen Mosher
	Topic 1: Bringing researchers to cloud computing	Tiffany Miller	NA	Helen Thompson
Dav2	Topic 2: Reproducibility and Interoperability of batch and ad hoc analyses	Jack DiGiovanna	NA	Natalie Kucher
2:35-3:50pm EDT	Topic 3: What technologies and data types are missing across platforms?	Ken Wiley	NA	David Higgins
23JUN2022	Topic 4: Diversifying genomic data science	Asiyah Lin	NA	Marcia Fournier
	Topic 5: Flagship use cases for interoperability	Michael Schatz	NA	Cara Mason

### Breakout 2



## Future: Administrative Coordinating Center (ACC)

#### **DEPARTMENT OF HEALTH & HUMAN SERVICES**

**Public Health Service** 

National Institutes of Health Bethesda, Maryland 20892

www.nih.gov

### March 16, 2022

**Research Opportunity Announcement** 

Research Opportunity Title: NIH Cloud Platform Interoperability Administrative Coordinating Center

#### OTA-22-004

Participating Organization(s): National Institutes of Health

**Components:** This Other Transactions Research Opportunity Announcement (OT ROA) is to support the *NIH Cloud Platform Interoperability* program (<u>NCPI</u>) and complements investments by NIH Institutes, Centers, and Offices (ICOs) in secure cloud-based platforms for data storage, sharing, and analysis. This research opportunity will be administered by the Office of Data Science Strategy (ODSS).

Funding Instrument: The funding instrument is the Other Transaction (OT) Award mechanism.

OT awards are not grants, cooperative agreements, or contracts, and use an Other Transactions Authority provided by law. Terms and conditions may vary between awards. Each award is therefore

## Search WG



Dave Rogers (Clever Canary) Kathy Reinold (Broad Institute)

## Overview

- Mission, Vision, Strategy
- Search Use Cases
- ODSS Search RFI Response
- Search Landscape Survey of the NCPI search ecosystem
- Search Demonstration Projects
- Next Steps
- Discussion

The NCPI Search Working Group, formed in October 2021, aims to:

- Accelerate the improvement of search interoperability across the participating NCPI platforms in support of NCPI's shared vision of a trans-NIH, federated data ecosystem.
- Focus on supporting federated dataset discovery, cohort creation, and knowledge discovery.

See the <u>NCPI Search Group Charter</u>

- We envision an integrated, federated, FAIR data ecosystem, supporting
  - data interoperability,
  - transparency of data provenance and quality,
  - researcher and participant equity.
- The Search Working Group advances this vision by identifying, evaluating, promoting, and demonstrating the effective use of data interoperability standards and guidelines.

## Target Search Use Cases / Modalities

Support search of studies and datasets across platforms by:

- experimental metadata such as assay, datatype, or study design,
- participant metadata such as medical history/treatment, behavioral metadata, environmental exposure, social determinants of health,
- observations made such as variants identified or the existence of other biomarkers,
- participant-consented allowable use.

- Be driven by researcher scientific use-cases.
- Advocate for a federated search architecture.
- Advocate for common standards for data models and APIs.
- Foster knowledge sharing across the NCPI search community.
- Solicit and facilitate NCPI Search Demonstration Projects to provide concrete examples of standards and guidelines in action.
- Promote the best open access view of managed access datasets

## **ODSS Search RFI Response Overview**

The NCPI Search Working Group's response to the NIH/ODSS Search RFI advocates:

- an open and federated data ecosystem,
- data standards adoption,
- exploring FHIR as an API solution for representing research data at the study metadata and individual level,
- investing in tools that enable the entire data collection, curation, submission and data sharing process to be infused with structured metadata/common data elements (CDEs).

See <u>NOT-OD-21-187 Request for Information (RFI): Search Capabilities across the</u> <u>Biomedical Landscape for NIH-wide Data Discovery</u>

## **RFI** Response Overview

Specific recommendations included:

- Establishing a "Minimum Study Metadata" standard to drive consistent discovery of program data.
- Advocating for data catalog and data explorer code reusability and multi-tenancy to help accelerate implementation timelines and drive consistency across programs.
- Aligning on standard ways to "push" cohorts from data repositories to analysis environments, and "pull" selected clinical and genomic variables of interest from data repositories to analysis environments.
- Aligning on a mechanism to support pan-NIH dataset search.

## Landscape Survey


- Purpose
  - Provide an overview of current search capabilities across NCPI platforms
  - Describe how we currently address search needs and understand the challenges

- Search capabilities represented in responses
  - AnVIL Gen3 Explorer, AnVIL Dataset Catalog
  - BioData Catalyst PIC-SURE, Dug
  - CRDC Cancer Data Aggregator (CDA) Search API
  - Kids First Data Portal, FHIR API
  - NCBI dbGaP Advanced Search, dbGaP FHIR API
  - NCPI Dataset Catalog

## Landscape Survey - Theme

### What search theme is most relevant for your users?


9 responses



## Landscape Survey - Data Modalities

What data modalities or types do you make available to users (assuming use has appropriate access rights)? Check all that apply.

9 responses



## Landscape Survey - Phenotype Standards

- Summary
  - Most reference ontologies
  - Clearly some variation

Standard	Responses
HPO	3
MESH	1
PhenX	1
Follow dbGaP guide	1
Annotated w/ ontology ids	1
SNOMED	1
LOINC	1
NCIT	1
ОМОР	1
CRDC Data Dictionaries/CRDC-H	1

## Landscape Survey - Standards

Genotype Standards

Standard	Responses
Ensemble	1
Follow dbGaP guide	1
NCIT	1
MIAME	1
CRDC Data Dictionaries/CRDC-H	1
Whatever platform provides	1
n/a or no response	3

Other Data Standards

Standard	Responses
MIAME	1
Follow dbGaP guide	1
SRA	1
DUO	1
CRDC Data Dictionaries/CRDC-H	1
n/a or no response	5

## Landscape Survey - Standards

- Non-phenotype data
  - Three responses reported this is not applicable
  - Of the other, generally one of the respondents reported the following
    - PubChem, EDAM, UBERON, OBI, dbGaP Submission Guide, SNOMED, LOINC, DICOM, OMOP, MONDO, ICD10, NCIT
  - Observation: Consider recommending specific ontologies for types of data
    - I.e. disease, lab tests, anatomy...
- Social Determinants of Health (SDoH)
  - One group reported storing this data in SQL database, another referenced dbGaP Submission criteria, others reported either not applicable or TBD
  - What standards cover this category well?

## Landscape Survey - Key Points

- Key technology enablers of cross-platform search & cohort building
  - Internet, common terminology, open APIs, interoperable data models, elastic search, FHIR API, subject-level and file metadata
- Key metadata for search
  - Subject/Patient demographic, phenotypic, whole organism tests, exposures
    - Does this include model organism or cell lines?
  - Samples/Biospecimen diagnosis (disease, treatments), assays/analysis performed
  - Subject, sample counts and of course provenance who, when, how...
  - Files data modality/type of analysis/experimental strategy/data type, data format
- Consent
  - Four groups search open data only, others reference dbGaP consent groups, DUO consent codes, RAS
- Security
  - One reference to RAS, 5 responses cite FISMA-moderate and FedRAMP certifications.

## Landscape Survey - Challenges

- Lack of metadata standards, lack of minimal standard
- Quality of metadata
- Lack of standardized APIs, APIs to pull data for indexing
- Different groups bringing their own data dictionaries
- Heterogeneity of data formats
- Lack of collaboration
- Better focus on the science
- Observation changing nature of data, data formats how to manage that?

Landscape Survey - Next Steps

• Continue to refine the survey with respect to data models and indexing methods.

• Publish the survey results on the NCPI Portal.

## **Demonstration Projects**

Several demonstration projects for specific use cases are in the proposal phase including:

- Uniform search of public sample and sequence read information across NCBI and Kids First repositories. Anne Deslattes Mays
- PIC-SURE NCPI Platform Integration Paul Avillach
- Filter studies by DUO codes on the NCPI Dataset Catalog Dave Rogers, Jonathan Lawson

See the <u>NCPI Use case Tracker</u>

- Recruit additional members.
- Solicit / recruit additional demonstration projects.
- Publish the landscape survey and additional analysis to the NCPI portal.
- Provide a survey of data model descriptions.
  - What are common tools used to describe data models?
  - Include those that allow for mapping/translation between data models or support schemas.
- Propose initial data model standards for discoverability.
  - Work closely with FHIR and Interop WGs
- Evolve strategy and refine near and longer term goals.

## Questions/Discussion?






### 1:05 PM - 1:35 PM EDT

# Technical Aspects of Interoperability



### 1:35 PM - 2:35 PM EDT

# The Texas Advanced Computing Center (TACC) as an Interoperable Cloud Resource for Biomedical Research



Dan Stanzione (TACC)

# THE TEXAS ADVANCED COMPUTING CENTER (TACC) AS AN INTEROPERABLE CLOUD RESOURCE FOR BIOMEDICAL RESEARCH

### **Dan Stanzione**

Executive Director, TACC Associate Vice President for Research, UT-Austin

Cloud Platform Interoperability Workshop June 2022

# **TACC - 2021**







# THE CHARGE FOR THIS TALK:

- How can TACC be leveraged for Biomedical Sciences?
- What resources are currently available?
- What technologies you are using to ensure interoperability with other systems?
- ▶ and some successful research examples for both basic and clinical research...
- ▶ (not necessarily in that order).



# TACC AT A GLANCE - 2021

### Personnel

185 Staff (~90 PhD)

### Facilities

12 MW Data center capacity Two office buildings, Three Datacenters, two visualization facilities, and a chilling plant.

### **Systems and Services**

15 production platforms, the #1 and #3 US academic supercomputers

Nine Billion compute hours per year5 Billion files, >100 Petabytes of Data,

### Usage

>15,000 direct users in >4,000 projects, >50,000 web/portal users, User demand 4x available system time. Thousands of training/outreach









# WHAT WE DO

- Provide researchers with:
  - Computing, Data, AI, Software capabilities to support their research
  - The expert help to be able to use it!
  - In the ways they want to consume it
  - Help with grants/strategy
- Computation, AI, Data almost ubiquitous acrost the sciences.



# SYSTEMS UPDATES A QUICK REMINDER ON OUR CURRENT MAJOR SYSTEMS

- Frontera, NSF Capability System, 2019-2025 (Currently #16)
- Stampede2, NSF Capacity System, 2017-2023 (Currently #47)
- Lonestar-6, Texas/Local System 2022-2027
- Longhorn AI/DL GPU System, 2019-2025
- ▶ Jetstream2 NSF "Cloud" System 2022-2027
- Chameleon NSF CS Testbed 2015-2024 (multiple HW upgrades)
- Corral, Ranch, Stockyard Storage Platforms
- ► Aggregate: ~75PF, ~16,000 compute nodes, ~350PB

The Texas Advanced Computing Center accelerates basic and applied cancer research to help save lives.

### **Computer Modeling**


Researchers use advanced computing to model tissues, cells and drug interactions, and to design patient-specific treatments and identify new medicines.


### **Big Data Analysis**

Supercomputers allow researchers to find patterns in genomes and among patient outcomes to pinpoint risks and target treatments.

#### Molecular Dynamics Simulations

Simulating protein and drug interactions at the atomic level enables scientists to understand cancer and design more effective therapies.





### Quantum Calculations

Exploring how proton and x-ray beams interact with DNA on the quantum level helps explain why radiation treatments work and how they can be optimized.

### **Trial Design**

Researchers use TACC's advanced computers to design clinical trials that can determine the combination of dosages that will be most effective.

### **Clinical Planning**

Supercomputers can test thousands of potential treatments in advance to help decide which one will work best.

### Artificial Intelligence


AI on high-performance computers can uncover relationships among complex cellular networks and reverse-engineer interventions.



with supercomputers

# Artificial intelligence and deep neural networks increased speed and efficiency for identification of head and neck cancers

- **Problem:** Contouring is the process by which radiation oncologists carefully review medical images of the patient to identify the gross tumor volume, then design patient-specific clinical target volumes that include surrounding tissues, since these regions can hide cancerous cells and provide pathways for metastasis. The process is quite subjective, and there is wide variability in how trained physicians contour the same patient's computed tomography (CT) scan.
- **Importance:** In the case of head and neck cancer, countouring is a particularly sensitive task due to the presence of vulnerable tissues in the vicinity. Better contouring can lead to determining best practices, so standards of care can emerge.



Comparison between computer-predicted ground-truth clinical target volume (CTV1) (blue) and physician manual contours (red)

Cancer (

lerson

enter


- Approach: Carlos Cardenas (MD Anderson) used Maverick to analyze data from 52 oropharyngeal cancer patients who had been treated at MD Anderson between January 2006 to August 2010, and had previously had their gross tumor volumes and clinical tumor volumes contoured for their radiation therapy treatment. He developed deep learning algorithm using auto-encoders — a form of neural networks that can learn how to represent datasets — to identify and recreate physician contouring patterns.
- Result: Cardenas and his collaborators tested the method on a subset of cases that had been left out of the training data. They found that their results were comparable to the work of trained oncologists. The predicted contours agreed closely with the ground-truth and could be implemented clinically, with only minor or no changes.

# TACC


https://www.tacc.utexas.edu/-/an-ai-oncologist-to-help-cancer-patients-worldwide

# Complex **computer models** and **analytic tools** to predict how cancer will progress in a specific individual

- **Problem:** The current state of cancer research is data-rich, but lacking governing laws and models. The solution may not be to mine large quantities of patient data, but to *mathemetize* cancer: to uncover the fundamental formulas that represent how cancer behaves.
- Importance: Accurate models could be used to predict the growth and decline of cancer and reactions to various therapies.



Snapshots of a tumor model with tumor cells growing in a healthy tissue at two time points and under different nutrient conditions



Model of tumor growth in a rat brain before radiation treatment (left) and after one session of radiotherapy (right)


- **Approach:** Researchers from Dell Medical School used Stampede2 to analyze patient-specific data from magnetic resonance imaging, positron emission tomography, x-ray computed tomography, biopsies and other factors, in order to develop their computational model.
- **Result:** The group was able to predict with 87 percent accuracy whether a breast cancer patient would respond positively to treatment after just one cycle of therapy.




https://www.tacc.utexas.edu/-/tailoring-cancer-treatments-to-individual-patients

# **TAPIS** and **Jetstream** enabled automated, real-time, quantitative magnetic resonance imaging

- Problem: Quantitative analysis of MR images is typically performed after the patient has left the scanner. Corrupted or poor quality images can result in patient call backs, delaying disease intervention.
- **Importance:** Real-time analytics of MRI scans can enable same-session quality control, reducing patient call backs, and it can enable precision medicine.





Platform to automate analysis tied to HPC resources

- **Approach:** Dr. Refaat Gabr (UTHealth) and Dr. Joe Allen (TACC) used the CyVerse SDK and Agave to help develop an automated platform for real-time MRI,
- **Result:** Scan data can now be automatically processed on high performance computing resources in real-time with no human intervention.



https://www.tacc.utexas.edu/-/real-time-mri-analysis-powered-by-supercomputers

### The Drug Discovery Portal empowers researchers worldwide to perform virtual screens on TACC HPC resources

- **Problem:** While *virtual screening* has compelling advantages over experimental methods alone, it requires high-performance computational resources, software licenses, and technical expertise, which may be unattainable for small academic labs.
- **Importance:** Successful structure-based virtual screening methods save time and resources in the drug discovery pipeline.


### Job Listing

C. D.C.

S Refresh					
Job Name	Job Type	Job Status	Job Start Time	Job End Time	Actions
2018.09.07-test2	vina	FINISHED	7-Sep-2018 03:31 pm	7-Sep-2018 03:32 pm	X Delete O Download Results
2018.09.07-test	vina	FINISHED	7-Sep-2018 03:11 pm	7-Sep-2018 03:11 pm	X Delete O Download Results
2018.09.05.test	vina	FINISHED	5-Sep-2018 08:39 am	5-Sep-2018 08:39 am	X Delete O Download Results
test-testset	vina	FINISHED	4-Sep-2018 12:46 pm	4-Sep-2018 12:47 pm	X Delete O Download Results
test_small	vina	FINISHED	12-Sep-2017 01:37 pm	12-Sep-2017 03:34 pm	X Delete O Download Results
test2	vina	FINISHED	12-Sep-2017 11:04 am	12-Sep-2017 11:06 am	X Delete O Download Results
tection	vina	EINIGHED	26- Jul-2017 10:20 am	26- Jul-2017 10:40 am	Delete     O     Developed Results


Job outputs are available for download in a web interface

utmb Health



#### Welcome to the new Virtual Drug Discovery Portal!

This Portal provides a graphical interface for conducting a screen for identifying small molecules that bind to your target protein.



- Approach: Dr. Stan Watowich (UTMB Galveston) partnered with researchers at TACC to provide an accessible and free virtual screening service called DrugDiscovery@TACC to investigators across the state of Texas and around the world.
- **Result:** Users upload proteins of interest into a friendly web interface, choose a ZINC library to screen, and results are returned typically within 24 hours. The efforts have led to dozens of documented drug candidate hits.


https://drugdiscovery.tacc.utexas.edu/


### Particle/Proton Therapy Translational Research Platform

Xiaodong Zhang (MDACC) Hang Liu (TACC)



Radiation Therapy: shooting high-energy particles to kill tumors while sparing healthy tissues





Photon vs Proton

25 GY unnecessary photon radiation

- 25000 x of the general public annual radiation limit
- 5000000 x of the intraoral X-ray
- Intensity Modulated Proton Therapy (IMPT) is the most advanced radiation therapy
- IMPT plan is to search all available solutions for how each proton beam modulated to deliver prescribed radiation
- Ideal IMPT plan is impossible to be achieved in the current clinically available computing environment
- □ The huge advantages of IMPT have NOT been fully utilized for majority of cancer patients



The University of Texas at Austin Oden Institute for Computational Engineering and Sciences





# Acute to Chronic Pain Signatures


A bold research initiative to identify biomarkers and advance pain science

- Multi-Center
- Protected Health Data Storage
- Protected Computing
- Virtual Biospecimen Data Repository
- Web browser accessible portal

# TARGETING TUMORS WITH NANOWORMS YING LI, UCONN

- "My research is centered on how to build high-fidelity, high-performance computing platforms to understand the complicated behaviors of these materials and the biological systems down to the nanoscale,"
- Nanoworms are long, thin, engineered encapsulations of drug contents.
- Modeled how these structures move in blood vessels of different geometries mimicking the constricted microvasculature.
  - Nanoworms can travel more efficiently through the bloodstream, passing through blockages where spherical or flat shapes get stuck.
  - ► Can use magnetic fields to influence flow.
- Can increase percentage of (highly toxic) drugs delivered directly to tumor.
- ▶ Published in Soft Matter, 2021.

TEXAS



# TECHNOLOGIES THAT HELP MOVE THINGS AROUND

- ► Containerization:
  - We support Singularity, Charliecloud, Apptainer, a few others the containerized workflows you build elsewhere will work at TACC
  - > Push your Docker images into Biocontainers or other repositories, we can run them in Singularity.
  - At this point, that's just good software engineering
- Standard Orchestration tools:
  - We support Slurm (for batch), Kubernetes (Services, Interactive sessions), JupyterLab (notebooks)
- Our data storage and formats are, umm, not exotic.
  - ► POSIX Files in repository
  - Standard connectors for relational databases.
  - We do have object stores if you really like them (S3 interface, like AWS)... codes like them more than people.



# TECHNOLOGIES THAT HELP MOVE THINGS AROUND

- Standard tools for interfacing, getting stuff in and out.
  - ssh/scp/gridftp for remote access
  - ► Google authenticator or others for multi-factor auth, where needed.
  - Open source TAPIS API for RESTFul web service access:
    - ▶ We've run this in AWS and Azure, as well as at TACC, and you could use it for free.
  - ► There are no "TACC specific" access/workflow/API tools.
  - Maybe the cloud should run more like us. . .
- We have computers, networks, storage systems, and a really good Linux image; you can run layers of your choice on that... What we recommend though:

# TECHNOLOGIES THAT HELP MOVE THINGS AROUND

- Don't build on vendor-specific services... Almost all have open equivalents.
- Use containers that run anywhere, methods to fetch from central repositories.
- But even when portable, data migration has a cost in money and time. And this
  adds up fast, so think about where your data is or should be.
- Plenty of our staff move back and forth ©.







# FHIR for Genomics: The Path Forward



Mullai Murugan (Baylor College of Medicine)

# **Overview - HL7 FHIR for Genomics**



### • <u>HL7</u>

• Healthcare Standards for the exchange, integration, sharing, and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services

### • FHIR (Core Specification)

- FHIR<sup>®</sup> Fast Healthcare Interoperability Resources is a next generation standards framework created by HL7. FHIR combines the best features of HL7's <u>v2</u>, <u>HL7 v3</u> and <u>CDA</u> product lines while leveraging the latest web standards and applying a tight focus on implementability.
- RESTful API
- Development heavily driven by implementations (see Argonaut)
- Insufficient genomics representation in R4 (latest release)

### • Clinical Genomics FHIR Implementation Guide (Specification)

- Profiles of existing FHIR resources to support exchange of genomic data
- Supports variant level data, variant level interpretations (inherited disease, somatic, PGx), report level interpretations, recommended follow-ups, report

# Clinical Genomics Genomics Reporting IG

HL7	Genomics Reporting Implementation Guide 2.1.0-SNAPSHOT - trial-use	19.0.3 Structures: Res		4.2 Defining Variants This Implementation Guide supports two reporting patterns for defining variants:		19.0.7 Terminology: Code Systems	
Home Table of Contents Background Artifact Index. Support + Quick Links+ Appendices+		These define constraints on FHIR resources for systems conforming to this implementation guide		1. By describing the change using HGVS or ISCN nomenclature. Example HGVS-styled variant. 2. By providing multiple component details similar to VCF columns. Example VCF-styled variant		These define new code systems used by systems conforming to this in	
Table of Contents	Home Page	Diagnostic Implication	Observation stating a linkage between one or more genotype/ha		orting pattern, different components MUST be used to properly define the varia s referencing external sources or increasing human readability of the instance.	ClinVar Evidence Level Exa	mple ClinVar contains examples of ex
enomics Reporting Implementation Guide, published by HL7 Clinical Genomics Working Group. This is not an author NAPSHOT). This version is based on the current content of https://dibub.com/HL7/genomics-reporting/ 3 and cham			condition, or cancer diagnosis.	Additional resources that implementers may want to leverage when reporting variant information i relationships among human variations and phenotypes, and NCBT's Variation Services(? that relies		Codes	https://www.ncbi.nlm.nih.gov/c relevant source.
			tion Task describing the follow-up that is recommended (2).				
Home Page		Genomics DocumentReference A profile of DocumentReference used to represent a genomi		fi 4.2.1 Variants Defined by a Nomenclature Statement		Coded Annotation Type Co	des Code System for specific types
.1 Scope ienomics is a rapidly e	1 Scope nomics is a rapidly evolving area of healthcare that involves complex data structures. There is significant value in sh		Genomics profile of DiagnosticReport.	This pattern describes the observed nucleotide sequence or configuration using HGVS or TSCN state property distinguish variants with the degree of precision needed for clinical use. Note that synony normalization may be required.		PharmGKB Evidence Level Example Codes	PharmGK8 contains examples on https://www.pharmgkb.org/pag
	le and that can accommodate ongoing evolution of medical science and practice. At present, th s - what data should be/might be present and how it should be organized. It does not address	New York Control of Co				charph couce	
	is - what data should be/might be present and how it should be organized, it does not address proved, routed, delivered, amended, etc.	Genotype	Assertion of a particular genotype on the basis of one or more v	Component	Example Value	Sequence Phase Relations Codes	Code System for specific types
this guide covers many	aspects of genomic data reporting, including:	Haplotype	Assertion of a particular haplotype on the basis of one or more v	genomic-hgvs (LOINC 81290-9) OF coding-hgvs (LOINC		To Be Determined Codes	These codes are currently 'TBD
	Representation of simple discrete variants, structural variants including copy number variants, complex variants as extra or missing chromosomes Representation of both known variants as well as fully describing de novo variations		Microsatellite Instability (MSI) is the condition of genetic hypern repair (MMR).		" code" : "NM_022787.3:c.769GsA"		validated.
						Variant Confidence Status	Codes A code that represents the conf
Germline and soma		Medication Recommendation	Task proposing medication recommendations based on genetic	cyogenomic- nomenclature (LOI)		L	
<ul> <li>Relevance of identified variations from the perspective of disease pathology, pharmacogenomics, transplant suitab.</li> <li>Full and partial DNA sequencing, including whole genome and exome studies</li> </ul>		Overall Interpretation Provides a coarse overall interpretation of the genomic results n	81291-7)	*wystem* : *urm:oid:2.16.848.1.113883.6.299*, *code* : *46.XX.t(9:22)(q34:q4)*			
		Overall Interpretation	Provides a coarse overall interpretation of the genomic results h		3	19.0.6 Terminology: Value Sets	
.2 How to Use		Region Studied	The Region Studied profile is used to assert actual regions studie				
his implementation guide is organized into a set of sections. All implementers intending to do clinical genomic reporti sporting sections. To understand the key profiles in this IG, as well as their relationship to one another, start with the yould review the Understanding FHIR section below.			coverage areas (e.g. due to technical limitations during test per	4.2.2 Variants defined by multiple components (VCF-like)		These define sets of codes used by systems conforming to this implementation golds	
			Indicates whether two entities are in Cis (same strand) or Trans	This representation leverages multiple component slices to communicate an allele within the conte definitional representation in FHIR, but is limited to variations with known breakpoints, and alleled specify genome build and chromosome identifiers rather than explicit reference sequences. Build a		Ended Availation Types Value Set	for specific types of ended accutations
he remaining sections provide support for more specialized types of reporting. If your system is involved with genom f the implementation guide for further guidance.						Condition Inventance Patterns Value Set	for specific transmission patterns of a condition in a pedigree
		Tumor Mutation Burden	The total number of mutations (changes) found in the DNA of or treatment. For example, tumors that have a high number of mu	Defining	Leona a second	DNA Change Type DNA Ches	ge Type of a variant.
lackground	Introduces some of the key genomics terms and relationships that should be understood b		Tumor mutational burden is being used as a type of biomarker.	Component	Example Value	Evidence Level Examples - Example	outon of values for Brideren Level
General Genomic Reporting	Overall guidance in using the profiles and transactions defined in this guide. Guidance and report overall interpretations and how to report genotypes, haplotypes, and different types	Therapeutic Implication	Profile with properties for observations that convey the potential Details about a set of changes in the tested sample compared to	genomic-ref-seq (LOINC 48013-7)	£	Functional Effect The effect	of a sociart on downstraine biological products or pathways.
fariant Reporting	Guidance on expressing information about variants gleaned from various sequencing appro array-based testino, etc.	rc			"system" : "http://www.ncbi.nlm.mih.gov/nuccore", "code" : "NC_000010.10"	Genetic Therapeutic Implications Value Set	for serves that cascelor a prodicted ramification based on the presenc
'harmacogenomic	anay-based testing, etc. Guidance and examples related to genomic testing done for the purpose of assessing genc for oncology and for general patient treatment.	Variant					set includes all HGNC Codes, which includes multiple code systems in consols, which must be seen with the HGNC game ID including the pr
Somatic Reporting	Guidance related to general patient deathent. Guidance related to genomic testing done on somatic (non-germline) tissues, including as				ROOS Structures, Extension D		

Genomics Reporting Implementation Guide, published by HL7 Clinical Genomics Working Group. This is SNAPSHOT). This version is based on the current content of https://github.com/HL7/genomics-reportin

Guidance related to genomic testing done for histocompatibility and immunogenomics ass

#### 3 General Genomic Reporting

listocompatibility


Reporting

This page defines the core profiles and concepts that would be expected to be present in most genomic r relate to each other. Concepts covered include the genomics report itself and the high-level categories of the report, such as patient, specimen, variants, haplotypes, genotypes, etc.

'his table describes	the categories of data contained in this implementation guide.
Senomics Report	Groups together all the structured data being reported for a genomic testing.
Overall Interpretations	Reported when variant analysis (sequencing or targeted variants) is done. Provide reported.
Genomic Findings	These are observations about the specimen's genomic characteristics. For example haplotype, or variant that was detected.
Genomic Implications	These represent observations where the Observation.subject is typically the Pa refer to Genomic Findings. For example, "Patient may have increased susceptibility
Region Studied	These are observations describing the region or regions that were studied as part
Other Observations	The results of tests other than sequenced genomic variants may also be included t.
Recommended Actions	Specific actions be taken, such as genomic counseling, re-testing, adjusting drug d
Contextual	Other resources that provide contextual details.

#### Genomics Report

The genomics report is the focus of all genomic reporting. It conveys metatotial about the versal report (that load (i.e., ). It also typical neuroloss a rendered version for review by a clinical. It also groups together all relevant infor will depret of the type of testing ordered, the reason for testing and the platicitis of the lab). Note of the structure recommendations that come with the report or expresses at PHK Tables(). The response to the organication structure that the specific CDM provides and the platicity of the results of the specific CDM provides and the report of the the specific CDM provides and the report of the specific CDM provides and the specific CDM provides and the specific CDM provides a



#### 19.0.5 Structures: Extension Detinitions

These define constraints on FHI	R data types for systems conforming to this implementation guide
Annotation Code	Codifies the content of an Annotation
Genomic Report Note	Adds codified notes to a report to capture additional content
Genomics Artifact	Captures citations, evidence and other supporting documentation for the observation or
Genomics File	Used to transmit the contents of or links to files that were produced as part of the testi similar files.
Genomics Risk Assessment	RiskAssessment delivered as part of a genomics report or observation
Medication Assessed	Used to reference a specific medication that was assessed (e.g. a FHIR Medication or a
Recommended Action	References a proposed action that is recommended based on the results of the diagnost
Therapy Assessed	Used to reference a specific therapy that was assessed (e.g. a FHIR ResearchStudy, a F

# New Implementers

- <u>Getting Started with Clinical Genomics for FHIR</u>
- Clinical Genomics Working Group Participation
- <u>Chat/Discussion boards</u>
- Tracking and ticketing system
- Genomics Reporting STU2 Implementation Guide
- Genomics Reporting Working Draft Implementation Guide



# FHIR Genomics - New Initiatives & Ongoing Effort




# **Genomics FHIR Initiatives**

- Genomics Reporting Implementation Guide STU2 Publication
  - General Clinical Genomic Reporting
  - Information for expressing information about variants
  - Pharmacogenomic Reporting
  - Histocompatibility Reporting
- New Genomic Study
- Other efforts
  - <u>GenomeX</u>, housed under the CodeX FHIR Accelerator
  - FHIR to OMOP



### Led by: **Robert Freimuth**, Mayo Clinic **HL7 FHIR Clin Gen WG IM Lead**




### Use Cases:

- Reports with multiple components
- -Multiple studies for same patient
- Consortia programs
- -Trio, T/N testing etc.


http://build.fhir.org/ig/HL7/genomics-reporting/branches/operations/OperationDefinition-find-study-metadata.html the standard strategy of the st

# Challenges, and the path forward

# Challenges, and the path forward



## 1. Clinical Genomics IG Learning Curve




For each variant reporting pattern, different components MUST be used to properly define the variant where possible. Other components MAY be used to provide additional information for cross referencing external sources or increasing human readability of the instance.



**Genomic Report Overview** 

# 2. Ease of Implementation



From publication "Genomic considerations for FHIR; eMERGE implementation

eMERGE III FHIR Pilot: Larry Babb, Broad Institute Luke Rasmussen, NU Casey Overby Taylor, JHU Mullai Murugan, BCM

# 3. Multiple Pilot Efforts

- 1. Creation of a FHIR specification and a pilot implementation for eMERGE Phase III;
- 2. Creation of a HLA Reporting IG based on the <u>Genomics Reporting IG (STU1)</u> led by Bob Milius at the NMDP;
- 3. A pilot project that utilizes the <u>Genomics Reporting IG (STU1)</u> at Cerner, in collaboration with a Diagnostic Laboratory.
  - Repi 1. Completed Major

4.

- 1. Composite Report Section Grouping
- 5. An c 2. Lab Defined Tests Methodology, References, etc... (PlanDefinition)
  - qGM 3. Report Level Comments Observation
    - 4. Recommendations (Proposed) -(RecommendedAction - Task)
    - <u>Nested & Indirect Result Referencing hasMembers &</u> derivedFrom?
    - 6. Addition of chromosome to Variant
- FHI 2.Completed Minor

Gen

- 1. New Identifier Type Code(s)
- 2. InhDisPath phenotype cardinality change
- 3. InhDisPath value (CC) made extensible
- 4. DR category cardinality changed to 0..\*


- 2.Completed Minor (cont'd)
  - 5. <u>RelatedArtifact extension in Observation Components</u> - Assessed Meds Citations (CG)
  - 6. <u>Distinction between Report Sign-Out/Off Date and</u> <u>Report Sent Date - (Sign Out = Issue) (OO)</u>
- 3.Pending
  - 1. <u>RecommendedAction Task reasonRef cardinality to</u> 0..\* (00)
  - 2. Add Age to US-Core Patient Profile (PatAdm)
  - 3. <u>Clinical vs Research Flag</u> (Core)
  - 4. Why is DR.code fixed to LOINC 81247-9? (CG)
  - 5. <u>RecommendedAction profile "code" should be</u> <u>extensible</u> (CG)

# 4. Diversity of the tech landscape

- Open Source
  - HAPI
  - Microsoft FHIR Server
  - <u>Etc</u>.
- Industry Sponsored
  - SMILE CDR
  - Microsoft Azure Based
  - AWS
  - Google
- EHR Vendors' FHIR servers
- SMART Apps

# 5. Adoption and direction

- EHR Systems/DLs Engagement
- Path setting research effort
- Standards integration
- Tech growth
- Mandates



## Acknowledgements

### eMERGE Phase III

EHRI subgroup FHIR Pilot subgroup Larry Babb, Broad Institute Ken Wiley, NHGRI Luke Rasmussen, NU Casey Overby Taylor, JHU

### HL7 FHIR Clinical Genomics (CG)

CG working group chairs CG working group members Robert Freimuth, Mayo Clinic, IM Ali Khalifa, Mayo Clinic, IM Arthur Hermann, GenomeX, KP May Terry, Mitre Corporation FHIR Core working group

### **ONC Sync for Genes Phase 3**

Allison Dennis, ONC Kevin Chaney, ONC Robert Freimuth, Mayo Clinic Robert Milius, NMDP Audacious Inquiry

### **Baylor College of Medicine**

Richard Gibbs Eric Venner Fei Yan Victoria Yi Supporting Genomic Data Sharing through the Global Alliance for Genomics and Health



Heidi Rehm (Broad Institute/MGH)

### The Global Alliance for Genomics and Health Mission...

The GA4GH aims to accelerate progress in genomic science and human health by developing standards and framing policies for responsible genomic and health-related data sharing.


### GA4GH achieves this by...

- **Convening** stakeholders
- **Creating** standards and harmonized approaches through community consensus
- **Catalyzing** sharing of data
- But **does not** generate data, nor build primary infrastructure or perform research/clinical care that our standards support

### **GA4GH Organization Structure**



Global Alliance for Genomics & Health



ga4gh.org

### **Different Approaches to Data Sharing**

### **Central Database**


Genomic Knowledgebase

### **Secure Cloud**

Large scale research datasets


#### **Federation**

Connecting national genomics initiatives



## **How GA4GH Works**

Discovery



ga4gh.org




## Challenges in rare disease gene discovery


•75% of rare disease cases remain unsolved

- 4,631 genes implicated in at least one disease but evidence for >10,000 more genes yet to be discovered for Mendelian disease (Bamshad, et al. AJHG 105, 448–455, 2019)
- The remaining genetic diseases are very, very rare difficult for any one investigator to amass enough cases to implicate a new disease gene

## **Principles of Gene Matching**



## Developing the MME Federated Network using GA4GH Standards





- API for data exchange ID (Mandatory) +/- Label Submitter (Mandatory) Phenotypic Features and/or Gene Names (Mandatory) Disorders (Optional) - OMIM or OrphaNet Sex, Age of Onset, Inheritance (Optional)
- Clinical and phenotypic data capture standards
- Consent framework for data sharing

<image><section-header>

Philippakis et al. The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery. Hum Mutat. 2015;36(10):915-21.

Buske et al. The Matchmaker Exchange API: automating patient matching through the exchange of structured phenotypic and genotypic profiles. Hum Mutat. 2015;36(10):922-7

16 papers in a special issue of Human Mutation (Vol 36, Issue 10, Oct 2015)

Large-Scale Genomics echnical Work Stream Data Use & **Researcher IDs** Cloud **Genomic Knowledge** Standards **Clinical & Phenotypic Data Capture Regulatory & Ethics** <sup>c</sup>oundation **Data Security** 


Discovery

## Human Mutation Variation, Informatics, and Disease

VOLUME 43 | ISSUE 6 | JUNE 2022

GARRY R. CUTTING, EDITOR

Special Issue: Matchmaker Exchange: Seven years of discovery and collaboration Guest Editors: Kym Boycott, Ada Hamosh, and Heidi Rehm



#### EDITORIAL INTRODUCTION Seven years since the launch of the Matchmaker Exchange: The evolution of genomic matchmaking

Kym M. Boycott, Danielle R. Azzariti, Ada Hamosh, Heidi L. Rehm Human Mutation. 2022;43:659–667. <u>https://doi.org/10.1002/humu.24373</u>

- The impact of GeneMatcher on international data sharing and collaboration
- PhenomeCentral: 7 years of rare diseas
- **DECIPHER:** Supporting the interpretatio variant data to advance diagnosis and res
- seqr: A web-based analysis and collabo
- PatientMatcher: A customizable Pythor rare disease patients via the Matchmaker
- The **RD-Connect Genome-Phenome An** gene discovery for rare diseases
- Advances in the development of PubCa interface and matching algorithm
- Over 10,000 candidate genes from ~200,000 patients from >12,000 contributors from 98 countries Over 1000 genes discovered through matchmaking
- ModelMatcher: A scientist-centric online platform to facilitate collaborations between
  stakeholders of rare and undiagnosed disease research
- Discovery of over 200 new and expanded genetic conditions using GeneMatcher

GeneDx Illumina Ambry

- A clinical laboratory's experience using GeneMatcher—Building stronger gene–disease relationships
- Diagnostic testing laboratories are valuable partners for disease gene discovery: 5-year experience with GeneMatcher
- · Variant-level matching for diagnosis and discovery: Challenges and opportunities
- Beacon v2 and Beacon networks: A "lingua franca" for federated data discovery in biomedical genomics, and beyond
- **Genomics4RD**: An integrated platform to share Canadian deep-phenotype and multiomic data for international rare disease gene discovery


#### Three clinical labs had 1040/3819 (27%) gene discoveries validated through MME


#### (a) Two-sided matchmaking



Matchmaker Exchange

(b) One-sided matchmaking





## VariantMatcher

VariantMatcher is a database open to search on genomic locations. It harbors genomic data as part of the BHCMG.

Email :		
hrehm@broadinstitute.org		
Password :		
	Log In	
	Login	

#### VariantMatcher (VM) created by:

- Nara Sobreira
- François Schiettecatte
- Ada Hamosh
- BHCMG Center for Mendelian Genomics

Your search included the following features: Hypotonia, Microcephaly, Global Developmental delay, Esotropia

A submission match notification, for your search: '6:34004293:T>C', was sent to the following: BHXXXX - Patient - Affected - 6:34004293:T>C Salmo Raskin - <u>genetika@genetika.com.br</u> - PUC Brazil Bilateral Cleft

BHXXXX - Patient - Affected - 6:34004293:T>C Hamza Aziz - haziz2@jhmi.edu - JHU Bicuspid Aortic valve, Aneurysm, ascending aortic

BHXXXX - Patient - Affected - 6:34004293:T>C Samantha Penney - penney@bcm.edu - Baylor College of Medicine Encephalopathy, Ataxia, Hypotonia

BHXXXX - Patient - Affected - 6:34004293:T>C Samantha Penney - penney@bcm.edu - Baylor College of Medicine Ataxia, Spasticity, adult onset spinocerebellar ataxia

BHXXXX - Mother - Unaffected - 6:34004293:T>C Filippo Vairo - <u>fvairo@hcpa.edu.br</u> - Hospital de Clinicas de Porto Alegre

BHXXXX - Father - 6:34004293:T>C Daryl Scott - <u>dscott@bcm.edu</u> - Baylor College of Medicine

BHXXXX - Mother - 6:34004293:T>C Samantha Penney - <u>penney@bcm.edu</u> - Baylor College of Medicine

BHXXXX - Father - 6:34004293:T>C Samantha Penney - penney@bcm.edu - Baylor College of Medicine

Please do not reply to this email, it was sent from an unattended email address; however, you can email us at <u>variantmatcher@jhmi.edu</u> or use the <u>contact form</u>.



INFORMATICS 🖻 Open Access 💿 😧 🗐 🗐

## Beacon v2 and Beacon networks: A "lingua franca" for federated data discovery in biomedical genomics, and beyond

Jordi Rambla 🗙 Michael Baudis 🗙 Roberto Ariosa, Tim Beck, Lauren A. Fromont, Arcadi Navarro, Rahel Paloots, Manuel Rueda, Gary Saunders, Babita Singh, John D. Spalding ... See all authors 🗸

First published: 17 March 2022 | https://doi.org/10.1002/humu.24369 | Citations: 1




DATABASES 🖻 Open Access 💿 🖲 😒

Variant-level matching for diagnosis and discovery: Challenges and opportunities


Eliete da S. Rodrigues, Sean Griffith, Renan Martin, Corina Antonescu, Jennifer E. Posey, Zeynep Coban-Akdemir, Shalini N. Jhangiani, Kimberly F. Doheny, James R. Lupski, David Valle ... See all authors  $\,\,\,\lor$ 

First published: 22 February 2022 | https://doi.org/10.1002/humu.24359 | Citations: 1


MyGene2, Geno2MP, VariantMatcher, Franklin



#### **IHCC Member Cohorts across the World**



GA4GH Marker Paper and other GA4GH Work Product Publications in November 2021 Issue of Cell Genomics



### **Cell Genomics**



Perspective

## GA4GH: International policies and standards for data sharing across genomic research and healthcare

Heidi L. Rehm,<sup>1,2,47</sup> Angela J.H. Page,<sup>1,3,\*</sup> Lindsay Smith,<sup>3,4</sup> Jeremy B. Adams,<sup>3,4</sup> Gil Alterovitz,<sup>5,47</sup> Lawrence J. Babb,<sup>1</sup> Maxmillian P. Barkley,<sup>6</sup> Michael Baudis,<sup>7,8</sup> Michael J.S. Beauvais,<sup>3,9</sup> Tim Beck,<sup>10</sup> Jacques S. Beckmann,<sup>11</sup> Sergi Beltran,<sup>12,13,14</sup> David Bernick,<sup>1</sup> Alexander Bernier,<sup>9</sup> James K. Bonfield,<sup>15</sup> Tiffany F. Boughtwood,<sup>16,17</sup> Guillaume Bourgue, 9,18 Sarion R. Bowers, 15 Anthony J. Brookes, 10 Michael Brudno, 18,19,20,21,38 Matthew H. Brush, 22 David Bujold,<sup>9,18,38</sup> Tony Burdett,<sup>23</sup> Orion J. Buske,<sup>24</sup> Moran N. Cabili,<sup>1</sup> Daniel L. Cameron,<sup>25,26</sup> Robert J. Carroll,<sup>27</sup> Esmeralda Casas-Silva,<sup>123</sup> Debyani Chakravarty,<sup>29</sup> Bimal P. Chaudhari,<sup>30,31</sup> Shu Hui Chen,<sup>32</sup> J. Michael Cherry,<sup>33</sup> Justina Chung.<sup>3,4</sup> Melissa Cline.<sup>34</sup> Hayley L. Clissold.<sup>15</sup> Robert M. Cook-Deegan.<sup>35</sup> Mélanie Courtot.<sup>23</sup> Fiona Cunningham, 23 Miro Cupak, 6 Robert M. Davies, 15 Danielle Denisko, 19 Megan J. Doerr, 36 Lena I. Dolman, 19 Edward S. Dove,38 L. Jonathan Dursi, 20,39 Stephanie O.M. Dyke,9 James A. Eddy,37 Karen Eilbeck,40 Kyle P. Ellrott,22 Susan Fairley, 3,23 Khalid A, Fakhro, 41,42 Helen V, Firth, 15,43 Michael S, Fitzsimons, 44 Marc Fiume, 6 Paul Ricek, 23 Ian M, Fore.<sup>29</sup> Mallory A, Freeberg.<sup>23</sup> Robert R, Freimuth.<sup>45</sup> Lauren A, Fromont.<sup>52</sup> Jonathan Fuerth.<sup>6</sup> Clara L, Gaff.<sup>16,17</sup> Weiniu Gan,33 Elena M, Ghanaim,46 David Glazer,47 Robert C, Green,148,49 Malachi Griffith,50 Obi L, Griffith,50 Robert L. Grossman, 44 Tudor Groza, 51 Jaime M. Guidry Auvil, 29 Roderic Guigó, 13,52 Dipayan Gupta, 23 Melissa A, Haendel,<sup>53</sup> Ada Hamosh,<sup>54</sup> David P, Hansen,<sup>16,83</sup> Reece K, Hart,<sup>1,100,124</sup> Dean Mitchell Hartley,<sup>55</sup> David Haussler, 35 Rachele M. Hendricks-Sturrup, 58 Calvin W.L. Ho, 57 Ashley E. Hobb, 6 Michael M. Hoffman, 19, 20, 21 Oliver M. Hofmann,<sup>26</sup> Petr Holub,<sup>58,59</sup> Jacob Shujui Hsu,<sup>60</sup> Jean-Pierre Hubaux,<sup>61</sup> Sarah E. Hunt,<sup>23</sup> Ammar Husami,<sup>62</sup> Julius O. Jacobsen, <sup>63</sup> Saumya S. Jamuar, <sup>64,65</sup> Elizabeth L. Janes, <sup>1,66</sup> Francis Jeanson, <sup>126</sup> Aina Jene, <sup>52</sup> Amber L. Johns, 67,68 Yann Joly,<sup>9</sup> Steven J.M. Jones, <sup>69</sup> Alexander Kanitz,<sup>8,70</sup> Kazuto Kato,<sup>71</sup> Thomas M. Keane,<sup>23,72</sup> Kristina Kekesi-Lafrance,<sup>3,9</sup> Jerome Kelleher,<sup>73</sup> Giselle Kerry,<sup>23</sup> Seik-Soon Khor,<sup>74,75</sup> Bartha M. Knoppers,<sup>9</sup> Melissa A, Konopko,78 Kenjiro Kosaki,77 Martin Kuba,59 Jonathan Lawson,1 Rasko Leinonen,23 Stephanie Li,13 Michael F, Lin, 78 Mikael Linden, 79,80 Xianglin Liu, 68 Isuru Udara Livanage, 23 Javier Lopez, 101 Anneke M, Lucassen, 81 Michael Lukowski,<sup>44</sup> Alice L. Mann,<sup>3,15</sup> John Marshall,<sup>58</sup> Michele Mattioni,<sup>82</sup> Aleiandro Metke-Jimenez,<sup>83</sup> Anna Middleton 84.85 Richard J, Milne, 84.85 Fruzsina Molnar-Gabor, 86 Nicola Mulder, 87 Monica C, Munoz-Torres, 53 Rishi Nag.23 Hidewaki Nakagawa, 88,89 Jamal Nasir, 90 Arcadi Navarro, 52,91,92,93 Tristan H. Nelson, 94 Ania Niewielska, 23 Amy Nisselle,<sup>17,28,95</sup> Jeffrey Niu,<sup>20</sup> Tommi H. Nyrönen,<sup>79,80</sup> Brian D. O'Connor,<sup>1</sup> Sabine Oesterle,<sup>8</sup> Soichi Ogishima,<sup>96</sup> Laura A.D. Paglione, 97,98 Emilio Palumbo, 13,52 Helen E. Parkinson, 23 Anthony A. Philippakis, 1 Angel D. Pizarro, 99 Andreas Prlic, <sup>100</sup> Jordi Rambla, <sup>13,52</sup> Augusto Rendon, <sup>101</sup> Renee A. Rider, <sup>46</sup> Peter N. Robinson, <sup>102,103</sup> Kurt W. Rodarmer, <sup>104</sup> Laura Lyman Rodriguez,<sup>105</sup> Alan F. Rubin,<sup>25,26</sup> Manuel Rueda,<sup>52</sup> Gregory A. Rushton,<sup>1</sup> Rosalyn S. Ryan,<sup>10</sup> Gary I. Saunders, 76 Helen Schuilenburg, 23 Torsten Schwede, 8.70 Serena Scollen, 76 Alexander Sent 10 Nathan C. Sheffield, 108 Neerjah Skantharajah, 3,4 Albert V. Smith, 109 Heidi J. Sofia, 46 Dylan Spalding, 79,80 Amanda B. Spurdle,<sup>110</sup> Zornitza Stark,<sup>16,17,26</sup> Lincoln D. Stein,<sup>4,19</sup> Makoto Suematsu,<sup>77</sup> Patrick Tan,<sup>84,111,112</sup> Jonathan A. Tedds, 76 Alastair A. Thomson, 33 Adrian Thorogood, 9.113 Timothy L. Tickle, 1 Katsushi Tokunaga, 75,114 Juha Törnroos, 71.60 David Torrents, 92,116 Sean Upchurch, 115 Alfonso Valencia, 92,116 Roman Valls Guimera, 20 Jessica Vamathevan,<sup>23</sup> Susheel Varma,<sup>23,117</sup> Danya F, Vears,<sup>17,28,95,118</sup> Coby Viner,<sup>19,20</sup> Oraig Voisin,<sup>119</sup> Alex H. Wagner, 31,32 Susan E. Wallace, 10 Brian P. Walsh, 22 Vivian Ota Wang, 29 Marc S. Williams, 34 Eva C. Winkler, 120 Barbara J. Wold,<sup>115</sup> Grant M. Wood,<sup>1</sup>J. Patrick Woolley,<sup>73</sup> Chisato Yamasaki,<sup>71</sup> Andrew D. Yates,<sup>23</sup> Christina K. Yung,<sup>4,121</sup> Lyndon J. Zass.<sup>87</sup> Ksenia Zavtseva.<sup>9,122</sup> Juniun Zhang,<sup>4</sup> Peter Goodhand,<sup>4,3</sup> Kathryn North,<sup>17,26</sup> and Ewan Birney<sup>23,123</sup>

### Get Involved! Visit GA4GH.ORG







Subscribe to GA4GH Updates ga4gh.org/subscribe Interoperability Opportunities & Challenges with the Cloud and STRIDES



Nick Weber (NIH STRIDES)

### Interoperability Opportunities & Challenges with STRIDES & Cloud NCPI Spring Workshop

### **Nick Weber**

Program Lead, NIH STRIDES Initiative | Program Manager, Cloud Services Center for Information Technology



June 23, 2022

### **NIH STRIDES Initiative**

The Science and Technology Research Infrastructure for Discovery, Experimentation, and Sustainability

- State-of-the-art data storage and computational capabilities
- Training and education for researchers
- Innovative technologies such as artificial intelligence and machine learning
- Professional engineering and technical support

### **Two Core Components of STRIDES**

### 1) Other Transaction Agreement

Enables NIH-funded institutions to leverage STRIDES benefits

### 2) NIH Enterprise Cloud Platforms & Services

Supports efficient and secure NIH-wide use of the cloud for IRP needs and/or ICs' institutional management



Example: U-Pitt enrolled in STRIDES. NIH-funded PIs supported by NIGMS (U24), NIDDK (U01), & NIDCD (R44) benefit from STRIDES discounts using the cloud to support their award/research activity

<u>Example</u>: NIA's Laboratory of Neurogenetics analyzes WGS data on the cloud for Parkinson's, Alzheimer's, and other dementias, and manages general lab infrastructure for data storage and deposition into the AMP PD data repository & knowledge platform

Cross-Cutting: Discounts, Training, Professional Services, & Vendor Support

## Sample of STRIDES-Supported Research Programs



## NEW: NIH Cloud Lab Offering

A cloud testbed allowing researchers to "try before they buy"

Primary Cloud Lab Use Cases



#### **Exploring the Cloud Consoles**

Researchers can gain an understanding of the look and feel of cloud environments before they jump into a full STRIDES account for research



#### Supplementing Cloud Training

Researchers can use the sandbox to strengthen their understanding of cloud training or follow along with training content in a separate environment.



#### **Experimenting with Simple Cloud Solutions**

Researchers interested in solutions for specific scientific tasks can use the sandbox to build proof of concept or other simple solutions to understand LOE and other details for production.

#### **Benchmarking Costs**

Testing out different tools and configurations (instance types, sizes, etc.) to optimize research analyses





### NIH Cloud Lab (continued)

NIH Cloud Lab is a no-cost (to you), 90-day pilot program that enables NIH-funded researchers to try commercial cloud services in an NIH-approved environment. The Cloud Lab provides training and guardrails to protect against financial and security risks.

## Full Access to the Cloud Console

- Deploy a full range of resources
- CPU or GPU VMs
- Managed Jupyter notebooks
- Advanced AI/ML capabilities
- Bioinformatic workflow managers
- Access to compute clusters

## Bioinformatic Tutorials to Speed Uptake

- Variant Calling
- GWAS
- Medical Imaging
- RNA seq
- Single Cell RNA seq
- Proteomics
- Using HPC environments in the cloud

## Broad Access Across the NIH Community

- Intramural
  - o AWS Beta Testing
  - o GCP Beta Testing
- Extramural
  - AWS Limited Beta Testing
  - GCP *Conditional* Limited Beta Testing

#### Let us know you're interested at: cloud.NIH.gov/resources/cloudlab

### **Interoperability Challenges & Considerations**

- New Data Management & Sharing Policy
- Modularity / portability / reusability

- Cross-cloud billing integration
- Cost enforcement
- Cost estimation

- Institution-level <u>data mesh</u> "nodes"?
- Pilot programs for standardization around products like Kubernetes, Docker, etc.?
- RAS as an underpinning for billing auth?
- NIH Cloud Lab examples / source code?
- NIH Cloud Lab & community contributions?

Interoperability is a challenge not only for data resources and analysis platforms built on the cloud, but for core cloud infrastructure itself

### Build Research Capacity in Partnership with Central IT's Cloud Ops Team

Interoperability in general requires mastery of the fundamentals (see: RAS); cloud infrastructure interoperability is no different



**Customer Engagement** 

Assessment & planning



#### Security

- · Identity & access management
- Vulnerability management
- Data protection & privacy
- · Security monitoring
- Infrastructure security hardening
- Incident response
- Cloud access security broker

#### **Service Management**

- Automated monitoring, ticketing & alerting
- 24/7 service desk operations
- Change & configuration management
- Incident & problem management
- Monitoring & event management
- Self service & service catalog

#### **Infrastructure Management**

- Platform & technologies setup
- Infrastructure provisioning
- Network provisioning and management
- Core infrastructure maintenance and modernization
- Disaster recovery & COOP

#### **DevOps and Automation**

- Release management
- Continuous integration
- Continuous deployment
- Cloud automation pipeline

# **Concurrent Breakout Session**

Topic 1: Bringing researchers to cloud computing	Tiffany Miller
Topic 2: Reproducibility and Interoperability of batch and ad hoc analyses	Jack DiGiovanna
Topic 3: What technologies and data types are missing across platforms?	Ken Wiley
Topic 4: Diversifying genomic data science	Asiyah Lin   Kim Albero
Topic 5: Flagship use cases for interoperability	Michael Schatz



## 2:35 PM - 3:50 PM EDT

## Topic 1: Bringing researchers to cloud computing

Barriers to bringing researchers to cloud computing	Strategies for getting around barrier	
"Expensive"- Academics can often view "on prem" as free, but everything that is not free is expensive. Furthermore, there is a notion of direct and indirect costs that must be budgeted. (Mike S)		
"Cost education/Fear of overspend" - Not understanding how much stuff costs in this new way of working	<ol> <li>Cloud Lab from Strides (maybe? If the user could make use of this on an analysis platform)</li> </ol>	
"Learning curve for doing science"- There is a learning curve and time must be spent preparing to use the cloud, translating pipelines to it, etc.	<ol> <li>Incentivizing learning w/ training awards?</li> </ol>	
"Value proposition"-Is the value of the cloud worth the time to learn?	<ol> <li>If we can educate folks on the 'jump off point' when working on the cloud can improve their ROI of time and money, a lot of the other barriers might become easier to address (Ravinder)</li> </ol>	
"Policy"- Aligning data policy w/ technology	<ul> <li>Educate Policy people and program officers and include in development</li> <li>Ex. Pick IC w/ knowledge of cloud and transfer knowledge over to NIBIB (just for example). Perhaps policy people transfer knowledge to other policies across ICs</li> </ul>	
"Which analysis platform is for you?" Do I use native compute, Terra, SBG? Etc.	<ol> <li>Map that shows where things are and why you'd choose this or that to learn</li> </ol>	

For notes and the table see here: https://docs.google.com/document/ d/1NnYE84dRLSRtCBtVc2j8aOskQfD AEIXcT-nPsDan3XQ/edit# Topic 2: Reproducibility and Interoperability of batch and ad hoc analyses

<u>Provenance</u> is a higher priority than perfect <u>reproducibility</u>


First step would be more information about data used

- <u>Metadata exchange</u> (dataset level, aggregate, subject level)
- <u>Accessioning space</u> (am I speaking AnVIL or KidsFirst, DOIs?)

Two types of data releases important for different goals

Provenance would help for multiple situations (retractions, submissions, bug-fixes, tool improvements)

We have many of the components for <u>analysis reproducibility</u> but are not yet at the point of checkpoint and restart



Topic 3: What technologies and data types are missing across platforms?

- Linking by phenotypes
  - Highly valuable for combining datasets together, but a lot of difficulties.
    - Phenotypes need to be standardized.
    - Need provenance how were these collected?
    - Negative phenotypes was a phenotype observed to be absent? Or not measured?
  - Tools that translate codes across ontologies would be helpful here.
- Clinical data notes
  - Can information be extracted out of these? Medical NLP tools?
    - One person's experience: still needs a bit to go.
    - Confused participants and their family members.
    - Can't translate and assign HPO terms.
  - Notes are not for the purpose of telling researchers info, they are for the patient care team.
    - Generally, physicians put notes all over the place. Professional note takers would help.
    - Billing codes could be useful, but again, not clinical focused.

## Topic 4: Diversifying genomic data science

Discussant: Asiyah Lin (NIH), Kim Albero (MITRE), Jay Ronquillo (NIH), Rabia Begum(Genome Medicine), Matthew Meersman (MITRE), Marcia Fournier (NIH), Michelle Salter(Deloitte)



In the first image, it is assumed that everyone will benefit from the same supports. They are being treated equally. In the second image, individuals are given different supports to make it possible for them to have equal access to the game. They are being treated equitably. In the third image, all three can see the game without any supports or accommodations because the cause of the inequity was addressed. The systemic barrier has been removed.

Link to Dr. Albero's slides

## Key points

•Data diversity in NCPI cloud platforms?

•Pull data together for small under-represented populations – larger cohort building

- •Utilize All of Us data
- •Ethical issues pulling data re-identify data privacy and security

•Provide a safe and secure environment for the under-represented or minority groups to involve in the science

•Missing the emphasize on diversity in our activities!

•Funding:

- •Congressional funding support for diversity related research
- •Adding diversity into the Funding Opportunity Announcement for NCPI

•Starting point: A small **data diversity investigation** to all NCPI platform datasets.

- report back to the next workshop.
- •Call for participation: asiyah.lin@nih.gov
- •Still a lot needs to be done in diversity, equity, and inclusive area

## Topic 5: Flagship use cases for interoperability

- We've heard quite a bit about Small Fish
  - Enabling small scale projects to effectively use what's already been built.
- Big Fish
  - Enable organizations and large scale projects
- Big Fish and small fish NCPI's success will be in achieving both
- New NIH data management sharing policy will enable broader sharing of processed data outcomes
  - Important to make interoperable
  - challenging to harmonize given that they have already been analyzed
- Generalist repositories : May be most effective for partially processed, open access data. The repositories do account for the long tail of data sharing.
  - How can researchers find data across the 7 or 8 generalized repositories?
  - How can we consistently share metrics across the repositories?

# Summary and Future Directions



Michael Schatz (Johns Hopkins University)